Stepped Care for Smoking Cessation: A Cost-Effectiveness Analysis and Simulation of Future Outcomes by Franklin, Brandi E.
University of Tennessee Health Science Center
UTHSC Digital Commons
Theses and Dissertations (ETD) College of Graduate Health Sciences
12-2009
Stepped Care for Smoking Cessation: A Cost-
Effectiveness Analysis and Simulation of Future
Outcomes
Brandi E. Franklin
University of Tennessee Health Science Center
Follow this and additional works at: https://dc.uthsc.edu/dissertations
Part of the Health and Medical Administration Commons
This Dissertation is brought to you for free and open access by the College of Graduate Health Sciences at UTHSC Digital Commons. It has been
accepted for inclusion in Theses and Dissertations (ETD) by an authorized administrator of UTHSC Digital Commons. For more information, please
contact jwelch30@uthsc.edu.
Recommended Citation
Franklin, Brandi E. , "Stepped Care for Smoking Cessation: A Cost-Effectiveness Analysis and Simulation of Future Outcomes"
(2009). Theses and Dissertations (ETD). Paper 78. http://dx.doi.org/10.21007/etd.cghs.2009.0097.
Stepped Care for Smoking Cessation: A Cost-Effectiveness Analysis and
Simulation of Future Outcomes
Document Type
Dissertation
Degree Name
Doctor of Philosophy (PhD)
Program
Health Science Administration
Research Advisor
Robert C. Klesges, PhD.
Committee
Joni Hersch, PhD Song Hee Hong, PhD Junling Wang, PhD Shelley White-Means, PhD
DOI
10.21007/etd.cghs.2009.0097
This dissertation is available at UTHSC Digital Commons: https://dc.uthsc.edu/dissertations/78
STEPPED CARE FOR SMOKING CESSATION: A  
COST-EFFECTIVENESS ANALYSIS AND SIMULATION OF FUTURE 
OUTCOMES 
 
 
 
 
 
 
 
 
A Dissertation 
Presented for 
The Graduate Studies Council 
The University of Tennessee 
Health Science Center 
 
 
 
 
 
 
In Partial Fulfillment 
Of the Requirements for the Degree 
Doctor of Philosophy 
From The University of Tennessee 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
By 
Brandi E. Franklin 
December 2009 
ii 
Copyright © 2009 by Brandi E. Franklin 
All rights reserved 
DEDICATION 
This dissertation is dedicated to the memory of my grandmother, Ms. Fannie 
Everett, my grandfather, Mr. Sammy Johnson, and my uncle, Mr. Bob Johnson. In 
addition, I dedicate this work to my parents, David and Sammie Everett, my siblings, my 
husband, Rodney Franklin, and my extended families (Everett, Johnson, Franklin, and 
Morris). Their love, support, and guidance have helped to shape me into a person in 
whom I take much pride!
iii 
ACKNOWLEDGEMENTS 
First and foremost, I give honor to God for the blessings of life and its abundance. 
I thank Him for strength, patience, and perseverance to realize such a great 
accomplishment. I am grateful for my parents, David and Sammie Everett, who have 
instilled in me Godly principles for living and continue to encourage and support my 
many endeavors. I also acknowledge the love and support of my sisters, Sadatra Gaines 
and Bridget Everett, and my extended family members. 
I thank my husband, Dr. Rodney Franklin, who brought me every flowchart he 
could find until I could develop my own! He endured many lengthy discussions of my 
dissertation, gripes about writing, revising, and formatting, and checked on me in wee 
hours of the morning to see if I was making progress. 
Finally, I’d like to acknowledge my committee members: Drs. Hong, Hersch, 
Klesges, White-Means, and Wong. Your contributions to this dissertation were 
invaluable. Thank you for your diligence and patience throughout this process. I also 
acknowledge my classmates for their input and support during my mock defense. This 
research could not have been conducted without the gracious support of National 
Institutes of Health (NIH) supplement grant funding (3R01CA106667-06S1). Thank you 
for your belief in this research endeavor. 
 
 
 
 
 
 
 
 
 
 
 
 
 
iv 
ABSTRACT 
It has been well established that smoking is the leading avoidable cause of 
premature morbidity and mortality in the United States and abroad. Smoking is 
attributable to over 400,000 annual deaths, and $193 billion in healthcare costs and lost 
productivity. Despite the apparent dangers and tremendous costs of tobacco use and 
dependence, smokers find difficulty quitting. Recently, stepped care has been proposed as 
a viable intensive approach for achieving long-term cessation. This research sought to 
evaluate cost-effectiveness of stepped care in a diverse population of smokers and 
analyze future health outcomes of smoking cessation. 
Cost-effectiveness analysis was conducted from an institutional perspective 
alongside an NIH-funded multi-site study, “Long-term Smoking Cessation Using 
Prescription Step Care” (STEP), which compared stepped care to a repeat care 
intervention. The outcome of interest was incremental cost per quit achieved by stepped 
care. Secondly, long-term cost-effectiveness of successful smoking cessation was 
analyzed using a societal perspective. A microsimulation model was developed to predict 
changes in morbidity and mortality over the lifetime for four smoking-related diseases 
(ischemic heart disease, cerebrovascular disease, lung cancer, and emphysema) due to 
successful cessation. Here, the outcome of interest was incremental cost per quality-
adjusted life year due to successful cessation. Lastly, sensitivity analyses were conducted 
to gauge robustness of estimates. 
 In the STEP study, costs for stepped versus repeat care were $875.09 and 
$422.26, respectively. Point-prevalence abstinence was validated among 20.5% (versus 
22.5%) of stepped care patients; continuous abstinence was achieved by 11.9% (versus 
14.3%) of stepped care patients. Stepped care was dominated by repeat care, being more 
costly but less effective. Stepped care produced a favorable incremental cost-
effectiveness ratio only among women achieving continuous abstinence in the Mayo 
sample. All other scenarios favored repeat care. When future outcomes of cessation were 
analyzed, average costs in original versus amended analyses were $49,025 and $48,956, 
respectively; QALYS gained were 8.62 and 8.6, for the aforementioned analyses. 
Successful cessation yielded incremental cost-effectiveness of $3,450 per QALY. In 
sensitivity analysis, incremental cost-effectiveness varied from cost-saving to $13,700 
per QALY. 
Stepped care was not cost-effective relative to repeat intervention. Quitting at the 
UTHSC site and among ethnic minorities was low, despite better rates of participation. 
Higher depression scores may have attributed to these results. Success of repeat care in 
STEP affirms findings of two recent studies. However, long-term cessation did prove 
highly cost-effective. Smoking cessation interventions continue to be extremely cost-
effective and provide sizable returns on investment to employers and payers alike; 
enhanced coverage of smoking cessation treatments and programs will likely increase 
quit attempts and ultimately, cessation. 
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CHAPTER 1: INTRODUCTION 
Overview 
Smoking remains the leading cause of premature death and disability in the 
United States. According to latest estimates, nearly one in five (19.8%) Americans 
smokes. Smoking claims over 438,000 lives each year, and contributes $40 billion in 
annual healthcare expenditures.1 Prevalence of smoking among adults stalled between 
2004 and 2006, following a seven year decline; 2007 estimates indicate a significant 
decrease in prevalence compared to the previous period. Despite efforts to curtail 
adolescent initiation and current smoking, declines in smoking among youth between 
1997 and 2003 have also stalled. In the United States, smoking prevalence is highest 
among youth and young adult groups, signaling cause for concern. Outside the United 
States, the toll of smoking on health is equally high. The World Health Organization 
(WHO) estimates that global tobacco use results in 5.4 million annual deaths—one every 
six seconds. Unless urgent action is taken, WHO expects that smoking will claim 1 
billion lives by the end of the 21st century.2  
Determinants of Smoking Patterns 
Most smokers initiate habits in adolescence or early adulthood. Several factors, 
both positive and negative, influence one’s decision to smoke. Figure 1-1, taken from the 
2000 Surgeon General’s Report, outlines several factors (protobacco and antitobacco) 
which may promote or deter one’s decision to initiate.3 For example, widespread social 
and community norms which support tobacco use, coupled with peer pressure, strategic 
marketing and placement of tobacco products in youth and community outlets, in the 
absence of antitobacco efforts, will negatively influence adolescents’ perceptions about 
smoking. Such factors support increased exposure to tobacco, which can lead to uptake. 
Conversely, implementation of educational initiatives, creation of nonsmoking social 
norms, and restrictions on tobacco marketing and product availability can delay or deter 
adolescent initiation. Likewise, these factors influence decisions for continued smoking, 
quitting, and relapse.  
Psychosocial factors strongly influence predisposition to smoking. A number of 
previous reports have revealed educational attainment as a strong sociodemographic 
predictor of smoking patterns.4-7 This correlation continues to be supported in recent 
literature, including new results from Meara and colleagues.8 Their analysis of changes in 
mortality and life expectancy from 1981-2000 concluded that education level is a 
mediator of life expectancy. Better educated individuals experienced a half-year increase 
from the 1980s to 1990s, and a 1.6 year increase from 1990-2000, while the less educated 
saw no changes during those periods. Moreover, the researchers found much of the 
mortality gap to be attributed to smoking related illnesses—namely lung cancer and 
chronic obstructive pulmonary disorder. Recent trends in quitting have paralleled those 
related to uptake and current smoking. Often, groups that exhibit the greatest likelihood 
of smoking behaviors are the least likely quitters.  
1 
 Figure 1-1. Factors Influencing the Decision to Smoke  
Source: U.S. Department of Health and Human Services. Reducing tobacco use : a 
Report of the Surgeon General. Rockville, MD: U.S. Department of Health and Human 
Services, Public Health Service, Office of the Surgeon General; 2000: p.7.3 
Personal Health Consequences 
 Smoking harms nearly every organ of the body, attributing to heart disease, stroke, 
certain cancers, pregnancy complications, and respiratory illnesses. Moreover, annual 
tobacco-related deaths surpass those caused by human immunodeficiency virus (HIV), 
illegal drug use, alcohol use, motor vehicle injuries, suicides, and murders combined.9 
Unfortunately, smokers ignore the risks associated with tobacco use, as tobacco-related 
disease may not surface for decades. Recent estimates reveal that premature death due to 
smoking takes, on average, 12 years of life.10 The Centers for Disease Control and 
Prevention reports that smokers are 2 to 4 times more likely to develop coronary heart 
disease than nonsmokers; coronary heart disease is the leading cause of death in the 
United States. Smokers also double their risk for stroke and are 10 times more likely to 
develop peripheral vascular disease, due to impaired circulation.11 Nearly all lung cancer 
deaths are attributable to smoking; other tobacco-related cancers include the bladder, oral 
cavity, pharynx, larynx, esophagus, cervix, kidney, lung, pancreas, and stomach. African-
American men have the highest rates of cancer related to smoking. Negative reproductive 
outcomes, including infertility, stillbirth, low birth weight delivery, and sudden infant 
death syndrome (SIDS) are typically attributable to prenatal smoking.11 Lastly, smoking 
can lead to asthma diagnosis and exacerbations, upper and lower respiratory illnesses and 
infections, and in most cases, emphysema.11 
Personal consequences of tobacco use, though delayed, are quite costly. In the last 
few decades, several estimates of personal costs of smoking have been published in the 
literature. One such study, conducted by Sloan et al., used available national data to 
estimate lifetime private and social costs attributable to smoking.12 They calculated a 
lifetime cost of $86,000 for a 24-year old woman; the cost increased to $183,000 for a 
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male the same age. If these costs were considered in cigarette pricing, the price per pack 
would be valued at $33. This accounted for both the cost of the product and the costs of 
resultant ill health. Viscusi and Hersch, in 2007, estimated personal mortality costs to 
smokers to be much higher than previous estimates, $222/pack for men and $94/pack for 
women.13 The differences lie in valuation methods. Sloan and others presume that loss of 
life due to smoking occurs at the end of life; these life-years supposedly have identical 
values that are discounted to the present to represent mortality costs. Viscusi and Hersch 
maintain that the “present value of the mortality cost of smoking is the discounted value 
of the incremental probability of death at different ages for smokers relative to otherwise 
comparable nonsmokers.” 
Societal Consequences 
Consequences of smoking extend beyond the individual; there is sufficient 
evidence to confirm that nonsmokers experience negative health effects from exposure to 
environmental tobacco smoke. 2, 14, 15 Passive smoking occurs when exhaled or ambient 
smoke from a cigarette (or related product) is inhaled by others. The U.S. Centers for 
Disease Control and Prevention estimates that 60% of Americans show biological 
evidence of second-hand smoke exposure, and that second-hand smoke causes 35,000 
deaths from coronary heart disease and 3,000 deaths from lung cancer among 
nonsmokers each year.  
Children are typically most vulnerable to environmental tobacco smoke exposure. 
Etzel and others report that approximately 42% of children 2 months to 11 years of age 
live in a home with at least 1 smoker and an estimated 8.7 to 12.4 million US children 
younger than 5 years are exposed to cigarette smoke at home.16, 17 These exposures place 
children at risk for asthma diagnosis and complications. Gilliland et al. and DiFranza et 
al. affirm the effects of prenatal and maternal smoke exposure on developmental lung 
defects, wheezing, and bronchial complications in children.18, 19 Additional research 
affirms that prenatal smoke exposure (PSE) explains above asthma-related and other 
health outcomes.18, 20-22  
Adults exposed to environmental tobacco smoke face similar consequences. In 
their recent report, Frieden and Blakeman found environmental tobacco exposure to be 
associated with 25% higher risk for chronic respiratory disease, 40-60% higher risk for 
developing asthma, and 50-100% higher risk for acute respiratory illnesses among 
adults.23 These effects take a detrimental toll on the labor force. In the United States, the 
Environmental Protection Agency estimates that second-hand smoke accounts for nearly 
3,000 annual lung cancer deaths among non-smokers in the country, though the 
methodology used to derive these estimates has been contested.24 Even abroad, the 
International Labor Organization estimates that at least 200,000 employees die annually 
due to exposure to smoke at work. In recent years, employers have responded by 
mandating smoke-free workplaces; these and other clean air acts should greatly reduce 
this number.25-28 
3 
Enstrom and Kabat have challenged these observations, purporting that health 
effects of secondhand smoke are exaggerated.29 In their 39-year study of environmental 
tobacco smoke exposure and related mortality among nonsmoking Californians, they 
found no significant evidence of a causal relationship between smoke exposure and 
tobacco related mortality. The authors argue that most epidemiologic studies show 
positive, yet statistically insignificant associations between environmental smoke 
exposure and coronary heart disease and lung cancer. Meta-analyses yield significant 
summary statistics, only when these data are combined, which do not provide strong 
enough evidence to establish causality. These challenges have likely gone unnoticed by 
consumers, whose perceptions about risks of second-hand smoke are relatively strong. 
Dr. Rick Blizzard, a consultant for Gallup Healthcare, captured Americans’ beliefs in a 
2004 poll regarding perceived effects of second-hand smoke.30 Over half of all 
respondents (54%) believed that second-hand smoke is “very harmful”. Specifically, 
women, more than men, held this view (63% and 44%, respectively). Another 32% of 
participants believed that second-hand smoke is “somewhat harmful”. Only 4% of all 
participants viewed second-hand smoke as not at all harmful. Younger respondents 
(under 50) were more likely to view second-hand smoke as harmful as compared to older 
respondents. These results may be due to enhanced efforts across the country to raise 
awareness about second-hand smoke and its consequences. 
The costs of smoking to society continue to grow drastically as more smokers live 
with tobacco-related illnesses. These rising costs have fueled greater efforts across the 
United States to promote smoking cessation. Costs of smoking are borne by employers, 
managed care companies, spouses and families, as well as the larger community. Thus, 
costs such as medical care (beyond the individual’s share), productivity, absenteeism, 
spousal and familial morbidity, mortality and disability, transportation, and caregiver 
time related to smoking must be considered. In 1998, Leonard Miller and his colleagues 
at University of California estimated a total annual cost of care for tobacco-related 
disease of $72.7 billion, using healthcare expenditure data from 1993.31 According to 
their analysis, smoking accounted for nearly 12% of all healthcare expenditures. In 
addition, they predicted that the actual cost of medical care for smoking-related diseases 
would swell to $1.8 trillion over the next 25 years. Current estimates are nearly $96 
billion for healthcare costs related to smoking. When productivity losses are included, 
that estimate doubles to approximately $193 billion in annual tobacco-related losses.10 
Barriers to Cessation 
Nicotine addiction is pervasive among smokers and remains a key barrier to long-
term smoking cessation .32 As the psychoactive drug element of tobacco products, 
nicotine produces chemical dependence similar to that of heroin, cocaine, or alcohol. 
Nearly three in four smokers report a desire to quit, but only a portion of them make 
successful quit attempts. While onset of disease is a typical driver of cessation; data from 
the 2006 National Health Insurance Study reveals significant age-adjusted smoking 
prevalence among patients with any smoking-related chronic disease (36.9%). One in 
five lung cancer patients and nearly half of those with emphysema in the sample were 
current smokers.15  For these reasons, expert panel members of the Agency for Health 
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Care Policy and Research (AHCPR) Clinical Practice Guidelines for Treating Tobacco 
Use and Dependence consider tobacco dependence a chronic disease requiring consistent, 
sustained intervention.33 Patients often require multiple attempts, as nicotine withdrawal 
symptoms can trigger relapse(s). Common withdrawal symptoms include nicotine 
craving, irritability, anxiety, difficulty concentrating, restlessness, and increased 
appetite.9 Weight gain relative to cessation is also a commonly cited concern among 
female smokers, especially those who are overweight or obese.34, 35 
Global Tobacco Control 
Significant efforts to control tobacco use in the United States began around the 
1960s, prompted by a landmark study of British doctors by Doll & Hill.36 Their 1954 
study definitively linked smoking and lung cancer; previous studies on tobacco’s harmful 
effects had been largely ignored. Researchers in the United States began similar 
observations of smoking and its effects. In 1964, the first report of the Surgeon General 
on smoking was released, initiating a unified movement in the U.S. toward reducing 
tobacco use. Since then, various tobacco control strategies targeting current smokers have 
been developed to promote cessation, namely pharmacotherapy and behavioral 
counseling. 
Pharmacotherapy 
Pharmacological therapy was first introduced in 1985 and has been used 
extensively over the past few decades to treat tobacco dependence. Pharmacological 
agents for smoking cessation typically fall into two major categories: nicotine 
replacement therapy (NRT) products and non-nicotine medications.9 Currently, seven 
pharmacologic agents are approved in the United States as first-line for treating tobacco 
dependence (5 NRT products and 2 non-nicotine products); these agents are highlighted 
in the U.S. Guidelines for Treating Tobacco Use and Dependence: 2008 Update.33 A 
large body of evidence exists which confirms the effectiveness and cost-effectiveness of 
these agents, used alone or in combination, in achieving cessation.  
Nicotine replacement therapies are designed to reduce withdrawal symptoms by 
substituting for some of the nicotine absorbed from tobacco.2 NRT products are available 
in various forms (patch, gum, inhaler, lozenge, nasal spray) and doses (0.5 mg-21 mg 
depending on product type). Most are sold over-the-counter in local pharmacy, retail, and 
grocery outlets; inhalers and nasal sprays require a prescription. Nicotine gums, lozenges, 
and inhalers deliver nicotine orally, patches deliver nicotine through the skin, and sprays 
deliver nicotine through the nasal cavity. Provision of a variety of NRT therapies 
enhances smoking cessation efforts across a broad range of smokers. Preference studies 
of nicotine replacement therapies reveal differential ratings of likability, perceived safety, 
and ease of use.37 Patches rank high for convenience; they are adhered once daily and 
provide sustained release of nicotine into the bloodstream. In contrast, smokeless tobacco 
users may find nicotine gum more appealing; its administration is similar to chewing 
tobacco, which (once activated) is placed between gum and cheek. Nicotine inhalers look 
like plastic cigarettes; their administration mimics the hand-to-mouth movement of 
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smoking. Nicotine nasal spray delivers nicotine to the bloodstream faster than any other 
form, making it a great choice for smokers who need immediate relief from cravings. 
Side effects of NRT are generally mild and well-tolerated; these vary by type.38 Most side 
effects associated with NRT are minimized when used appropriately. 
Besides nicotine replacement therapies, two non-nicotine medications, bupropion 
and varenicline, can also be used first-line. Bupropion was approved in 1997 as a 
smoking cessation aid, marketed as Zyban. It is also sold as the antidepressant Wellbutrin 
in the United States. Bupropion is a relatively weak inhibitor of the neuronal uptake of 
norepinephrine, serotonin, and dopamine, and does not inhibit monoamine oxidase. The 
mechanism by which bupropion enhances the ability of patients to abstain from smoking 
is unknown. However, it is presumed that this action is mediated by noradrenergic and/or 
dopaminergic mechanisms.39 Varenicline, marketed as Chantix, is the first partial agonist 
of the α4β2 neuronal nicotinic acetylcholine receptor to be developed.38 The efficacy of 
varenicline in smoking cessation is believed to be the result of its activity at a sub-type of 
the nicotinic receptor where its binding produces agonist activity, while simultaneously 
preventing nicotine binding to α4β2 receptors.40 Both bupropion and varenicline are 
associated with side effects. Bupropion users commonly report dry mouth and insomnia; 
these are well tolerated and usually disappear after a few weeks. Hypertension has also 
been reported. Common side effects of varenicline include nausea, insomnia, and 
abnormal dreams. In addition, varenicline has become increasingly associated with 
neuropsychiatric symptoms including changes in behavior, agitation, depressed mood, 
suicidal ideation and suicidal behavior that may lead to discontinuation of therapy.41 
These non-nicotine medications are available only by prescription. 
Duration of pharmacotherapy ranges from a few weeks to six months and 
treatment courses vary by product. In the Guidelines for Treating Tobacco Use and 
Dependence, doses and recommendations for administration and duration are outlined for 
all pharmacotherapies. Details for first-line agents are listed in Table 1-1. Wide 
variations in duration and dosing indicate that treatment can be tailored to individual 
preferences, dependence levels, and cessation history to enhance effectiveness. Assuming 
daily cigarette consumption of one pack per day and treatment duration of six weeks 
using nicotine patches, the typical smoker would begin with a daily dose of 21 mg for 
four weeks, followed by two weeks at the 14 mg dose, and 7 mg for the final two weeks. 
Most NRT treatment courses involve step-down dosing and depend on the cigarette 
consumption of the smoker; however, dosing increases over the treatment period for non-
nicotine medications. Patients interested in using pharmacotherapy to aid cessation 
should consult their physician to determine which product(s) are most effective. In 
addition, patient preferences and prior experiences with pharmacotherapy should be 
considered when recommending a particular form for smoking cessation. Misuse of 
nicotine replacement therapy is commonly cited in the literature, likely due to improper 
administration, misconceptions of effectiveness, and safety concerns. Schneider and 
others encourage sampling of smoking cessation therapies as a method for improving 
treatment outcomes.37,42 When used appropriately, smokers can decrease their 
dependence on nicotine and quit smoking permanently.   
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Table 1-1. First-Line Pharmacotherapies for Smoking Cessation 
Pharmacotherapy 
Treatment 
length Dosage Cost 
Nicotine gum 4-12 weeks 2 mg or 4 mg dose; 1 piece/ 
1-2 h; NMT 24 pieces/day1 
$48/box 2 mg, 
$63/box 4 mg2 
Nicotine patch Varies3 Various doses; 21 mg 
patch/day for 4 weeks, then 
14 mg patch/day for 2 
weeks, then 7 mg patch/day 
for 2 weeks 
$37/box 7 mg, 
$47/box 14 
mg, $48/box 
21 mg 
Nicotine inhaler Up to 6 
months 
4 mg; 6-16 cartridges/day, 
then tapered dosing final 6-
12 weeks4 
$197/box (168 
10mg 
cartridges) 
Nicotine nasal spray 3-6 months 0.5 mg/nostril (1-mg dose); 
1-2 doses/h; at least 8 
doses/day, NMT 40 
doses/day 
$49/bottle 
(~100 doses) 
Nicotine lozenge 6-12 weeks 2 mg or 4 mg5; 1 lozenge/1-
2 h for 6 weeks, then 1 
lozenge/2-4 h for weeks 7-
9, then 1 lozenge/4-8 h for 
weeks 10-12 
$34/box 2 mg, 
$38/box 4 mg 
(72 
lozenges/box) 
Bupropion 7-12 weeks; 
Up to 6 
months 
150 mg daily for three days; 
then 150 mg twice daily 
$97/month (60 
tablets) 
Varenicline 3-6 months 0.5 mg/day for 3 days, then 
0.5 mg twice daily for 4 
days, then 1 mg twice daily 
$131/month 
(56 tablets) 
1Dose depends on cigarette consumption 
22 mg box (100-170 pieces); 4 mg box (100-110 pieces) 
3Treatment of 8 weeks or less as efficacious as longer periods 
4A 10 mg cartridge delivers a 4 mg dose 
5Dose depends on nicotine dependence 
Abbreviations: h-hour, NMT- no more than 
Source: Fiore MC, Jaén CR, Baker TB et al. Treating tobacco use and dependence: 2008 
update. Clinical Practice Guideline ed. Rockville, MD: Department of Health and Human 
Services. Public Health Service; 2008.33 
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Effectiveness of nicotine replacement therapies has been widely established, with 
well over 3,000 studies published to date. In meta-analyses, NRT in all forms exhibited 
similar efficacy, doubling cessation rates when compared to no therapy.43-45 Results of 
meta-analyses of bupropion and varenicline confirm that these non-nicotine agents are 
more effective than NRT in producing abstinence.46-49 When NRT products are used in 
combination with other NRT agents or in combination with non-nicotine products, they 
produce even higher rates of cessation than any pharmacotherapy alone. Combination 
NRT and non-nicotine medication therapy is well tolerated.  Pharmacotherapies for 
smoking cessation are highly cost-effective; this is well established in the literature. 
Incremental cost-effectiveness figures in smoking cessation typically fall well below 
established thresholds of $20,000/life-year saved and $50,000/QALY.50  
  When treatments with first-line therapies fail, two second-line non-nicotine 
agents, clonidine and nortriptyline, can be used to aid in smoking cessation.33 Clonidine 
is a hypertensive agent available as a tablet or transdermal patch for smoking cessation 
treatment. Dosing ranges from 0.10-0.75 mg/daily (oral) or 0.10-0.20 mg/daily 
(transdermal) for up to 12 weeks. Though well-tolerated, clonidine use is associated with 
dry mouth, drowsiness, dizziness, and sedation. Clonidine cannot be stopped abruptly; is 
must be tapered to avoid sharp increases in blood pressure and catecholamine levels. 
Nortriptyline is an older antidepressant that can be used second-line for smoking 
cessation. Its mechanism of action (in tobacco dependence) is largely unknown. Dosing 
begins at 25 mg daily, and typically increases to 75 mg or 100 mg for up to 12 weeks. 
Common side effects include sedation, dry mouth, lightheadedness, and shaky hands. 
Abrupt discontinuation of nortriptyline can cause withdrawal; patients must be carefully 
monitored when using this agent for smoking cessation. Neither of these agents has been 
FDA-approved for smoking cessation; however, adequate evidence of efficacy and safety 
exists. 
Behavioral Counseling 
 Behavioral counseling is a viable alternative or adjunct to pharmacotherapy for 
smoking cessation. Counseling is usually individually tailored, ranges from brief advice 
to intensive counseling, and is conducted through various media (i.e. in person, by 
telephone, via internet or printed materials). Group counseling methods also exist, but 
will not be discussed here. Counseling on smoking cessation is generally provided by 
primary care clinicians, but can be delivered by other health professionals (i.e. nurses, 
pharmacists, dentists, psychologists) across a variety of settings (i.e. hospitals, clinics, 
quitlines). The physician/patient encounter is an optimal opportunity to provide practical 
counseling (problem-solving). This type of behavioral counseling educates smokers on 
recognizing situations that trigger smoking/relapse, developing coping skills, and 
emphasizing the dangers of smoking and the benefits of quitting. Intra- and extra-
treatment social support counseling can also utilized. Here, practitioners provide 
additional support, encouraging patients to express their concerns about quitting and 
identifying external support systems to aid patients through the cessation process. 
As an alternative to face-to-face counseling, telephone quitlines provide an 
effective medium for targeting smokers to encourage cessation. Quitlines eliminate most 
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barriers associated with face-to-face counseling, including transportation, 
patient/provider availability, and cost.51 Consequently, quitlines can reach more smokers, 
especially vulnerable groups for whom services are not offered. California initiated the 
first publicly funded telephone quitline in 1992 as part of its state tobacco control 
program.51,52 By 2004, 37 other states had established their own; all states now operate 
quitlines. In the last decade, quitline use increased substantially enough to be analyzed 
separately in the 2008 Guidelines.33  
Like pharmacotherapy, behavioral counseling methods have proven effective 
across a variety of settings and smoking populations. Behavioral counseling is widely 
used for pregnant smokers, due to inadequate evidence to confirm the efficacy and safety 
of pharmacotherapy use.53 Meta-analyses show that brief counsel by a health professional 
provides some benefit, but increased intensity of counseling (increased number or length 
of sessions) is associated with more than a two-fold increase in cessation rates.33 Due to 
its established efficacy, the U.S. Public Health Service now recommends that health 
professionals screen all patients for smoking status and advise smokers on strategies for 
quitting. Counseling is appropriate for all smokers, though the strategy employed is 
determined by the patient’s motivation to quit. At minimum, every smoker should be 
counseled on the five “A”s, as detailed by the Guidelines:53 
1. Ask all patients whether they smoke and if they are interested in quitting. 
2. Advise patients about the health risks associated with tobacco use and the 
benefits of quitting. 
3. Assess a patient’s readiness to quit. For example, is the patient ready to 
quit in the 1-6 months? 
4. Assist in the quit process by educating patients about strategies such as 
adding pharmacotherapy and making behavioral changes, which will 
improve their success. 
5. Arrange for follow-up by phone or in person to improve the patient’s 
likelihood for success. 
For smokers motivated to quit, this initial session should yield a viable strategy for 
cessation. If a smoker is not yet motivated, clinicians should probe for potential barriers 
to cessation and continue emphasizing the 5 “A”s, risks associated with smoking, as well 
as benefits of cessation during subsequent visits.  
Despite its effectiveness, use of behavioral counseling is challenged by several 
factors. Research indicates that disparities in the provision and utilization of counseling 
persist. Cokkinides et al. demonstrated in analyses of 2000 and 2005 National Health 
Interview Survey (NHIS) data that compared to whites, black and Hispanic smokers were 
significantly less likely to be screened for tobacco use, receive advice to quit, or use 
tobacco cessation treatment.54, 55 Across the two survey periods, receipt of advice to quit 
among smokers surveyed increased only modestly (53% to 61%). Despite the increased 
reach of quitlines, they too are underutilized. In a qualitative review of surgical patients 
and providers, Warner et al. found that both groups had limited knowledge of quitlines.56 
Providers indicated willingness to refer patients to quitlines, but reported time as a key 
barrier to receiving training in smoking cessation interventions. A report of quitline 
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operations for 2004 revealed that most quitlines offered proactive versus reactive 
counseling (89.5% versus 62.2%), mainly through proactive referrals from physicians.51 
While proactive telephone counseling is considered effective, little research has been 
conducted to establish the efficacy of smoker-initiated telephone counsel relative to other 
methods.57  In addition, Sood et al highlights that smokers may not be interested in 
intensive counseling methods, which among highly dependent smokers may be necessary 
for cessation.57 
Future Efforts 
Tobacco control efforts have contributed to the significant decline in smoking 
prevalence, now reduced by nearly half.  The decline in tobacco use has produced a 
resultant decline in mortality, though life expectancy increases have yielded an increasing 
proportion of deaths caused by the chronic diseases associated with smoking—primarily 
cancer, cardiovascular disease, and emphysema.3 However, much work remains. Hughes 
purports that smokers able to quit have already done so, leaving older recalcitrant 
smokers likely exhibiting higher levels of nicotine dependence, depression, and comorbid 
substance abuse.58 A review of cessation interventions among these smokers indicate a 
lack of responsiveness to treatment.59 Newer cessation methods have been proposed to 
address this more difficult-to-treat smoking population.  
Stepped Care for Tobacco Cessation 
Stepped care has surfaced as an intensive approach that could possibly improve 
long-term cessation rates among smokers. Stepped care is defined as the practice of 
initiating treatment with low-intensity intervention, exposing treatment failures to more 
intense intervention at subsequent steps until the desired outcome is reached. Stepped 
care is not an intervention in itself. Rather, it is a way to sequence interventions so that 
the intensity, complexity, and costs of care are guided by each patient’s observed 
outcome.60 Stepped care, as a treatment approach, has been employed extensively in the 
management of hypertension. Current and previous reports of the Joint National 
Committee on Prevention, Detection, Evaluation, and Treatment of Blood Pressure 
present a hypertension stepped care algorithm combining empirically validated treatment 
strategies in three areas: lifestyle modification, first-line pharmacologic agents, and 
second-line combination regimens.  Treatment recommendations vary depending on risk, 
degree of blood pressure elevation, evidence of target organ damage, and presence of 
cardiovascular disease, medication side effects, and other risk factors.61 Stepped care is 
advocated in various guidelines for treatment of asthma,62 rheumatoid arthritis,63 
diabetes,64 depression,65 and has been explored in treatment of various chronic disorders 
including back pain,60 migraine,66 obesity,67 eating disorders,68 multiple sclerosis,69 
alcohol dependence,70-72 and heroin dependence.73 
Evidence of the efficacy of stepped care in treating nicotine dependence has not 
been established; only a few published studies exist investigating this new approach.74, 75 
Reid and colleagues examined the viability of stepped care among 254 smokers 
hospitalized with coronary artery disease.74 Patients were randomized to receive either 
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usual care, consisting of brief counsel, or intensive stepped care, which combined brief 
counsel and pharmacotherapy. After three months, short-term cessation rates favored 
stepped care, but this trend was not sustained at one year. The authors attributed the 
results to timing and content of the stepped care intervention. Specifically, initial 
treatment was limited by duration of inpatient stay, and patients were not followed up 
until four weeks post-discharge. This delay in assessing quit status made it difficult to 
prevent relapse in the interim. For relapsers, three counseling sessions and up to eight 
weeks of nicotine replacement therapy were offered, which showed benefit only at three 
months. Similarly, a study by Smith and colleagues failed to demonstrate that either of 
two stepped care treatments improved long-term cessation above brief intervention.75 
They too attributed poor results to a one week delay in offering step up therapy, a period 
most critical to relapse. Thus, panel members contributing to the AHCPR guidelines have 
not made a formal recommendation for stepped care approaches to smoking cessation.33 
Purpose of Study 
Stepped care provides a framework for achieving professional support for chronic 
illness that is cost-effective and is based on patients' observed response to treatment.70 It 
promotes efficient resource allocation, by exposing only treatment failures to more 
intensive therapy.76 A current research study, CA106667: “Long-term Smoking Cessation 
Using Prescription Step Care” (STEP), explores a novel, aggressive stepped care 
approach to increasing tobacco cessation relative to a repeat therapy approach. However, 
the stepped care approach in this study (relative to previous studies) more closely aligns 
with methods in hypertensive care, in which therapy (pharmacologic and behavioral) is 
intensified over a maximum of three steps to increase likelihood of cessation by study 
end. Investigators expect the study to yield more favorable results than seen previously 
because of its increased intensity and duration. Moreover, it is necessary to determine 
cost-effectiveness of stepped care in smoking cessation, as only one study to date has 
examined this.77 Thus, the purpose of this research is to use results from the 
aforementioned STEP study to ascertain if stepped care relative to repeat care is a cost-
effective method for achieving tobacco cessation.  
STEP is a multi-site study comprised of participants in Memphis, Tennessee and 
Rochester, Minnesota. Participants are at least 18 years old and self-reported smokers of 
at least 10 cigarettes per day, who have consented to participate in the research study. 
This group serves as the cohort for the cost-effectiveness analysis. Though smokers 
across both sites are typically one-pack-a-day smokers and have similar levels of nicotine 
dependence, it is important to note the unique differences that exist among smokers 
across study sites. Smokers in Memphis fit the typical demographic profile—they are 
mainly low income and minority. The National Institutes of Health has deemed low 
income and minority smokers as special populations which require greater study, as these 
populations exhibit low rates of cessation, especially long-term. Minority race and low 
socioeconomic status are factors which primarily drive disparities in tobacco cessation. In 
addition, Memphis smokers in the sample have higher CES-D (Center for Epidemiologic 
Studies Depression Scale) scores compared to Rochester smokers (9.84 vs. 7.59); CES-D 
scores indicate severity of depressive symptoms. Smokers in Rochester, Minnesota are a 
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strong contrast to those in Memphis; they are primarily Caucasian and have higher 
income levels. In fact, minorities only comprise about 9% of the Rochester sample, as 
compared to 50% in the Memphis sample. Recruitment through Mayo Clinic may 
influence these differences as the recruited sample mirrors the Rochester, Minnesota 
population. Baseline characteristics for the sample are detailed further in Chapter 3. 
Specific Aims 
Evaluate Cost-Effectiveness of the STEP Study 
Data collected from the research study will be used to conduct a cost-
effectiveness analysis. The primary outcome of interest is incremental cost per quit for 
stepped care versus repeat care. Although the research study defines three cessation 
measures (point-prevalent, prolonged, and continuous) to be captured, point prevalent 
and continuous abstinence are most commonly cited in previous studies and will be used 
to calculate incremental cost per quit. Given the research setting, costs will reflect study 
rates.  
Use Study Outcomes to Simulate Future Health Consequences 
Simulation models are widely used in healthcare interventions to simulate future 
events. Results from the study can be used to predict changes in disease risk, incidence, 
and mortality resulting from cessation. Use of simulation models (microsimulation, 
discrete event simulation) in healthcare studies is gaining popularity. These methods 
transcend the constraints of Markov modeling in their ability to better predict individuals’ 
movement through a disease or health process. Individual characteristics of study 
participants are used as model inputs to simulate impacts of long-term cessation (i.e. 
change in morbidity and mortality) in a diverse population and its resultant impact on 
societal costs. Results of the simulation are presented as incremental cost per quality-
adjusted life year (QALY). Because health-related quality of life measures are not 
provided in the STEP study, synthetic estimates from the literature can be substituted. 
Short-term and long-term STEP outcomes can then be analyzed against previous studies.  
Compare Cost-Effectiveness Results to Previous Analyses 
Results of the cost-effectiveness analyses for STEP will be compared to other 
studies reviewed in the literature. By using multiple outcomes measures, study results can 
be compared to a broad range of literature. Most cost-effectiveness analyses of smoking 
cessation interventions use cost per quit as a primary measure. Cost per QALY is 
generally the standard measure used in cost-effectiveness analyses of other major life-
saving health interventions; it allows for easier comparison and comprehension and 
ultimately broadens the audience for whom cost-effectiveness research can benefit.  
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Conceptual Framework of STEP Study 
The conceptual framework which grounds the cost-effectiveness analysis is 
derived from the framework of the original intervention, described in Figure 1-2. The 
model is based on principles of social and operant learning and combines psychosocial, 
neuropharmacologic, and environmental determinants of tobacco use at several levels.  
At the top of the diagram, a variety of factors predispose individuals to smoking 
including social (culture, socioeconomic status, media/family/peer influences), 
psychological (comorbidity, personality, stress), and biological (genetics, nutrition) 
factors. These and other factors, such as nicotine dependence or past attempts to quit, will 
influence a smoker’s motivation to make one or more attempts to quit. Cessation 
represents an opportunity for new learning (which opposes the previous learned behavior 
of smoking); this will no doubt effect both one’s motivation to make a quit attempt and 
his/her self-efficacy (belief about the ability to quit) (box 3). A novel approach (box 2) to 
cessation can positively influence motivation to quit, outcomes expectancies, and 
smokers’ belief in their ability to quit. It is expected that a novel approach will increase 
readiness to quit (box 4) and lead to a quit attempt (box 5).   
After a quit, risk of relapse exists, especially as nicotine withdrawal symptoms 
surface. As seen in the diagram, predisposing factors (i.e. nicotine dependence) again will 
influence risk factors which often lead to relapse. Negative affect or weight gain may 
prompt smokers to resort to older learning, thus retuning to smoking. Therefore, 
reinforcement is provided (i.e. phone calls, mailings) to discourage relapse and encourage  
Behavioral
Pharmacologic
Cognitive Factors 
(3)
?Motivation
?Outcome 
expectancies
?Self-efficacy
N
ov
el
ty
(2
)
Readiness 
(4)
Quit 
Attempt 
(5)
Risk and Protective 
Factors for Relapse (6)
?Withdrawal
?Negative affect
?Weight change
?Social support
?Exposure to smokers
?Situational crises
Maintenance 
(7)
Dose
Predisposing Factors (1)
?Dependence
?Smoking history
?Prior quit attempts
?Demographics
?Environmental factors
Relapse (8)
Recycle 
(9)
 
Figure 1-2. Conceptual Framework of STEP Study 
Source: Klesges, RC. Step Care Manual of Procedures. 2006: p.11 (unpublished).78  
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maintenance of cessation (box 7). Smoking status is determined several weeks following 
treatment; in case an individual returns to smoking (box 8), a smoker is recycled quickly 
(box 9) into a renewed quit attempt. For stepped care patients who relapse, the dose of 
pharmacological and behavioral therapy is “stepped up”; this intensified intervention is 
presented as new novel approach to make another quit attempt. Stepped care offers a new 
opportunity for learning at each quit attempt; by presenting an alternative novel therapy, 
motivation, outcome expectancies, and self-efficacy remain positive instead of becoming 
negative. Smokers offered stepped care will be more likely to make additional quit 
attempts. Each new attempt increases one’s likelihood of cessation through an increased 
number of trials. Over time, the probability of quitting is expected to increase with the 
number of quit attempts in a negatively accelerated pattern.  
Significance  
Several factors justify significance of this research. First, the underlying 
intervention evaluates a new method for smoking cessation. Given the current difficulties 
of achieving both short- and long-term cessation among smokers ready to quit, providing 
a new approach can boost cessation efforts across the United States and abroad. 
Moreover, this intervention features a significant portion of minority and low-income 
smokers; cessation has proven far more difficult to achieve in this population. These 
results will inform current research on establishing effective interventions to achieve 
cessation in key populations. In the most recent AHCPR guidelines, Fiore and colleagues 
highlight low-income individuals and racial/ethnic minorities as special populations for 
which more effective intervention is needed.33 In addition, they stated that stepped-care 
interventions in smoking cessation warranted further research, due to its paucity in 
current practice.  
The economic evaluation connected to the intervention will contribute positively 
to a growing body of literature assessing cost-effectiveness of smoking cessation studies 
and programs. O’Sullivan, Gold, and others contend that conducting economic evaluation 
alongside studies is feasible and convenient.79, 80 Growth in this area of the literature is 
critically necessary to inform policymakers of the value of smoking cessation to society. 
Currently, the lack of standards in the use of cost-effectiveness for funding smoking 
cessation has resulted in sub-optimal uptake in the coverage of such programs across 
health plans. Several studies have demonstrated both increased participation and 
improved outcomes in cessation health plan-sponsored programs that cover all or part of 
costs. These benefits are enhanced with coverage of related pharmacologic therapies to 
help more smokers kick their habits. 
Additionally, the growing burden of U.S. healthcare costs on taxpayers, 
businesses, and government will build evidence to encourage the government to establish 
national standards for economic evaluation of new drug therapies and disease 
management programs, and set thresholds for justification of coverage. Many countries 
already mandate cost-effectiveness analysis as a requirement for approval and coverage 
of new drug therapies, and have realized significant cost savings. 
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Definition of Terms 
• Biochemical verification. The use of biological samples (expired air, blood, 
saliva, or urine) to measure tobacco-related compounds such as thiocyanate, 
cotinine, nicotine, and carboxyhemoglobin to verify users’ reports of abstinence. 
 
• Bupropion (bupropion). A non-nicotine aid for smoking cessation, originally 
developed and marketed as an antidepressant. It is chemically unrelated to 
tricyclics, tetracyclics, selective serotonin re-uptake inhibitors, or other known 
antidepressant medications. Its mechanism of action is presumed to be mediated 
through its capacity to block the reuptake of dopamine and norepinephrine 
centrally. Marketed as Zyban for smoking cessation. 
 
• Cost-effectiveness. A ratio of costs incurred and averted by a particular treatment 
or service and the benefits achieved by treatment/service. 
 
• Efficacy. The outcome achieved from a treatment provided under near-ideal 
circumstances of control (typically, in a research study). Efficacy studies involve 
recruitment of motivated participants, random assignment, intensive assessment, 
and methods designed to keep participants in treatment. 
 
• Environmental tobacco smoke (ETS). Also known as “secondhand smoke” 
(SHS) or passive smoke. The smoke inhaled by an individual not actively 
engaged in smoking, but who is exposed to smoke from the lit end of a cigarette 
and the smoke exhaled by the smoker. 
 
• Failure (treatment). Defined by self-reported relapse or abnormal biochemical 
measure (expired carbon monoxide or cotinine measure) 
 
• Intensive interventions. Comprehensive treatments that may occur over multiple 
visits for long periods of time and may be provided by more than one clinician. 
 
• Intervention. An action or program that aims to bring about identifiable 
outcomes. In tobacco dependence treatment, the intervention generally is clinical 
in nature and may consist of counseling and the use of medications. Also referred 
to as “treatment.” 
 
• Nicotine gum. Nicotine-containing gum, a smoking cessation aid, that delivers 
nicotine through the oral mucosa. It is available without a prescription. 
 
• Nicotine patch. A nicotine-containing patch, a smoking cessation aid, that 
delivers nicotine through the skin; available with or without a prescription. 
 
• Nicotine replacement therapy (NRT). Refers to medications containing nicotine 
that are intended to promote smoking cessation. There are five NRT delivery 
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systems currently approved for use in the United States. These include nicotine 
gum, nicotine inhaler, nicotine lozenge, nicotine nasal spray, and nicotine patch. 
 
• Point prevalence abstinence. A measure of tobacco abstinence based on 
smoking/tobacco use occurrence within a set period (usually 7 days), prior to a 
follow-up assessment. 
 
• Prolonged abstinence. A measure of tobacco abstinence based on whether 
subjects are continuously abstinent from smoking/tobacco use from their quit day 
to a designated outcome point (e.g., end of treatment, 6 months after the quit day). 
 
• Quality-adjusted life years (QALY). Measure of both the quality and the 
quantity of life lived. Used as a means of quantifying the benefits of a medical 
intervention. 
 
• Quit. Successful cessation attempt, reported by self-reported or biochemically 
verified abstinence (where appropriate). 
 
• Randomized controlled trial. A study in which subjects are assigned to 
conditions on the basis of chance, and where at least one of the conditions is a 
control or comparison condition. 
 
• Relapse. Return to regular smoking by someone who has quit. A distinction is 
sometimes made between “relapse” and a “lapse” (or a “slip”), which is a return 
to reduced smoking or brief smoking after quitting that falls short of a return to 
regular smoking. 
 
• Self-reported abstinence. Abstinence based on the patient’s claim, which may or 
may not be verified clinically by biochemical confirmation. 
 
• Serum nicotine. Level of nicotine in the blood. This often is used to assess a 
patient’s tobacco/nicotine self-administration prior to quitting, and to confirm 
abstinence self-reports during follow-up. Nicotine commonly is measured in urine 
and saliva. 
 
• Serum nicotine/cotinine levels. Level of nicotine/cotinine in the blood. Cotinine 
is nicotine’s major metabolite, which has a significantly longer half-life than 
nicotine. This often is used to estimate a patient’s tobacco/nicotine self-
administration prior to quitting, and to confirm abstinence self-reports during 
follow-up. Cotinine commonly is measured in urine and saliva. 
 
• Smoker. A person that uses tobacco products in any form. 
 
• Smokeless tobacco. Any form of unburned tobacco, including chewing tobacco, 
snus, and snuff. Smokeless tobacco can cause cancer of the gum, cheek, lip, 
mouth, tongue, throat, and pancreas. 
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• Stepped care. The practice of initiating treatment with a low-intensity 
intervention and then exposing treatment failures to successively more intense 
interventions. 
 
• Tobacco dependence. Dependence on any form of tobacco, including, but not 
exclusive to, cigarettes, pipes, cigars, and chewing tobacco. 
 
• Varenicline. A non-nicotine aid for smoking cessation, and the first partial 
agonist of the α4β2 neuronal nicotinic acetylcholine receptor to be developed. It is 
presumed to work by preventing nicotine binding to α4β2 receptors. Varenicline 
is marketed in the United States as Chantix.  
 
• Withdrawal symptoms. A variety of unpleasant symptoms (e.g., difficulty 
concentrating, irritability, anxiety, anger, depressed mood, sleep disturbance, and 
craving) that occur after use of an addictive drug is reduced or stopped. 
Withdrawal symptoms are thought to increase the risk for relapse. 
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CHAPTER 2: LITERATURE REVIEW 
Introduction 
In WHO’s 2008 report, six major policies are introduced that, when enacted 
together, will help prevent young people from initiating smoking, help current smokers 
quit, and protect nonsmokers from unnecessary secondhand exposure.2 Offering to help 
smokers quit is a key policy that encourages use of low-cost, effective interventions to 
increase cessation. Currently, such programs exist in nine countries, representing 5% of 
the world’s smoking population. Thus, information on cost-effectiveness of smoking 
cessation interventions is critical to justify funding of future studies and coverage of 
smoking cessation programs for smokers. 
To this end, a review of literature of cost-effectiveness analyses in smoking 
cessation was conducted. The PubMed database was queried to identify full-text articles 
(including literature reviews and meta-analyses) that met these criteria: a) smoking 
cessation clinical trials/studies analyzing (or simulating) either a stepped care 
intervention or a moderate/intensive pharmacotherapy and counseling intervention, b) a 
cost-effectiveness component, c) face-to-face contact for interventions (versus telephone 
or mail contact only), and d) end-of-study follow-up of at least 12 months post initiation. 
These specific criteria were necessary for relevant comparison to the Step Care study. 
Articles had to clearly state a perspective (i.e. societal, third-party payer), cessation and 
outcomes measures, patient population, and duration of follow-up to be considered for 
review. Articles using return on investment or cost-benefit techniques or those analyzing 
cost-effectiveness of anti-smoking policies or taxes (instead of treatments or programs) 
were excluded. Analyses conducted in other countries were included as long as articles 
were printed in English and met all other criteria.  Medical Subject Heading (MeSH) 
terms (costs and cost analysis, tobacco use cessation/economics) produced close to 100 
full-text results; only nine met inclusion criteria. Following a brief overview, studies were 
analyzed in two areas: comparisons of cost-effectiveness and adherence to widely 
accepted recommendations for conduct of economic evaluations. 
 Overview of Smoking Cessation Studies 
 Nine studies utilizing intervention designs most comparable to the underlying 
study are reviewed to estimate an expected range of cost-effectiveness for the Step Care 
Study. Considering that these studies use shorter treatment periods, it is expected that 
they will provide a lower bound for expected cost-effectiveness of Step Care. The studies 
reviewed assess the impact of smoking cessation interventions across varied time 
horizons (18 months to lifetime); Table 2-1 outlines study characteristics. Only one study 
(Barnett)77 among those reviewed analyzed cost-effectiveness of a stepped care 
intervention (relative to brief intervention); all others compared brief interventions to 
other moderate or intensive interventions. Short-term studies analyzing intermediate 
outcomes (i.e. cost per quit) are reviewed separately from those analyzing long-term 
outcomes (i.e. cost per life-year saved, cost per QALY). 
Table 2-1. Study Characteristics: Cost-Effectiveness Analyses of Smoking Cessation 
Interventions 
Study, Year 
Characteristics Barnett et al. (2008) Bolin et al. (2006) Cornuz et al. (2003) 
Methods       
Analysis type Prospective CEA Prospective CEA Prospective CEA 
Model type decision tree simulation model Markov model 
    
Framing    
Country United States Sweden Switzerland 
Setting 322 smokers in a 
mental health 
outpatient setting 
Model cohort of 
male & female 
smokers, 
proportionate to 
Swedish population 
simulated twin 
cohorts of one PAD 
smokers 
Intervention 1. Brief counsel and 
list of SC programs 
(reference) 
1. Bupropion 1. Counseling only 
from GP (reference) 
 2. Stepped care* 2. Nicotine gum 2. Counseling plus 
gum 
  3. Nicotine patch 3. Counseling plus 
patch 
   4. Counseling plus 
spray 
   5. Counseling plus 
inhaler 
   6. Counseling plus 
bupropion 
    
Perspective Research Societal Third-party payer 
Time horizon 18 month follow-up 
following treatment 
20-year follow-up 12 month follow-up 
following treatment 
    
Effects    
Cessation  Point-prevalence Continuous Point-prevalence 
Main effects  1. C/Q 1. C/QALY 1. C/LYS 
   
Discount rate N/A 3% 3%  
   
Base year (costs) 2003 2001 2001 
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Table 2-1. (continued) 
Study, Year 
Characteristics Cornuz et al. (2006) 
Feenstra et al. 
(2005) Gilbert et al. (2004) 
Methods       
Analysis type Prospective CEA CEA of cessation 
programs 
Prospective CEA 
Model type Markov model simulation model Markov model 
Framing    
Country Multiple countries The Netherlands Seychelles 
Setting simulated twin 
cohorts of one PAD 
smokers 
simulated cohort of 
Netherlands 
population 
simulated twin 
cohorts of one PAD 
smokers 
Intervention 1. Counseling only 
from GP (reference) 
1. Minimal 
counseling (MC) 
1. Counseling only 
from GP (reference)
 2. Counseling plus 
gum 
2. MC + NRT 2. Counseling plus 
gum 
 3. Counseling plus 
patch 
3. Intensive 
counseling (IC) + 
NRT 
3. Counseling plus 
patch 
 4. Counseling plus 
spray 
4. IC + Bupropion 4. Counseling plus 
spray 
 5. Counseling plus 
inhaler 
5. Telephone 
counseling (TC) 
5. Counseling plus 
inhaler 
 6. Counseling plus 
bupropion 
6. Current practice 
(reference) 
6. Counseling plus 
bupropion 
    
Perspective Third-party payer Societal Third-party payer 
Time horizon 12 month follow-up 
following treatment 
75 years 12 month follow-up 
post treatment 
Effects    
Cessation Point-prevalence Prolonged 
abstinence  
Point-prevalence 
Main effects 1. C/LYS 1. C/Q 1. C/LYS 
  2. C/LYS  
 3. C/QALY  
Discount rate 3%  4% 3%  
    
Base year (costs) 2001 2000 (euros) 2003 
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Table 2-1. (continued) 
Study, Year 
Characteristics Hall et al. (2005) Wasley et al. (1997) Woolacott (2002) 
Methods       
Analysis type Retrospective CEA  Prospective CEA Prospective CEA 
Model type decision tree decision model decision model 
Framing    
Country United States United States United Kingdom 
Setting 220 cigarette 
smokers 
Hypothesized 
sample of 
established PAD 
smokers 
Hypothesized 
sample of 
established United 
Kingdom smokers 
Intervention 1. Medical 
management (MM) 
(reference) 
1. Counsel 
(reference) 
1. Counsel only 
(reference) 
 2. MM + PI 2. Counsel + patch 2. NRT + counsel 
 3. MM + Nortrip  3. Bupr + counsel 
 4. MM + Bupr  4. NRT + Bupr + 
counsel 
Perspective Third-party payer Patient Third-party payer 
(NHS) 
Time horizon 52 weeks following 
initiation 
12 months following 
treatment 
Lifetime 
Effects    
Cessation Point-prevalence Point-prevalence Point-prevalence 
Main effects 1. C/Q 1. C/Q 1. C/Q 
  2. C/LYS 2. C/LYS 
   3. C/QALY 
Discount rate N/A 5% 1.5% (effects only) 
Base year (costs) 2000 1995 1998 
Note: *Stepped care involves: 1) up to 3 assessments of Readiness to Quit, 2) NRT and 6 
counsel sessions, and 3) Bupropion and 2 additional counsel sessions. 
Abbreviations: CEA: cost-effectiveness analysis; C/LYS: cost per life-year saved; C/Q: 
cost per quit; C/QALY: cost per quality adjusted life-year; G: gum; GP: general 
practitioner; I: inhaler; IC: intensive counseling; MC: minimal counseling; MI: 
motivational interviewing; MM: medical management; N/A: not applicable; NHS: 
National Health Service (United Kingdom); NRT: nicotine replacement therapy; P: patch; 
PAD: pack-a-day (20+ cigarettes); PI: psychological intervention; RCT: randomized 
controlled trial; SC: smoking cessation; TC: telephone counseling. 
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Short-Term Studies 
Barnett et al. randomized 322 smokers in a mental health outpatient setting to a 
brief contact intervention (comprising one counseling session and a list of available 
smoking cessation programs) or a stepped care intervention.77 Stepped care participants 
were offered up to three assessments of readiness to quit; contemplators or requestors of 
therapy were then offered six counseling sessions and 10 weeks of nicotine replacement 
therapy. Two additional counseling sessions and bupropion pharmacotherapy were 
offered as a third step, upon relapse. Point-prevalence abstinence (7-day) was verified at 
3,6,12, and 18 months. At study end, 24.6% of stepped care participants versus 19.1% of 
brief contact were abstinent, at an incremental cost of $6,204 per additional quit.  
Hall et al. examined incremental cost-effectiveness of bupropion, nortriptyline, 
and psychological intervention when added to medical management among San 
Francisco area volunteers participating in a clinical trial.81 Here, medical management 
comprised four brief counseling sessions in which physicians gave advice to quit, 
medication education and monitoring, and other materials, while psychological 
intervention involved five group sessions, providing more in-depth counsel and support. 
Nortriptyline and bupropion were pharmacotherapy options; all interventions were 
conducted over 12 weeks. Seven-day point prevalence abstinence was verified at end of 
treatments and at weeks 24, 36, and 52. Incremental cost-effectiveness estimates for 
psychological intervention, nortriptyline, and bupropion were $440, $741, and $1,509 per 
quit, respectively. Hypothesis testing revealed that differences in cost-effectiveness of 
therapies were not significant. 
Long-Term Studies 
Bolin et al. evaluated the cost-effectiveness of bupropion and motivational 
support relative to NRT (patch and gum) and motivational support for a cohort of 
smokers simulating the Swedish population.82 A model was constructed to analyze 
treatment costs incurred, healthcare costs averted (due to decreased risk of disease), and 
productivity gains realized due to smoking cessation over a 20-year horizon. A variety of 
external data sources were used for estimating quit, relapse, disease incidence, and 
mortality rates and treatment costs that were entered into the model. Bupropion was 
dominant to both nicotine gum and nicotine patch therapies for men and women in the 
simulation when direct and indirect costs of smoking cessation were considered; 
bupropion was less costly and more effective, producing net cost savings. However, 
when only direct costs were considered, bupropion remained dominant only when 
compared to nicotine gum therapy. Bupropion was cost-effective (more costly but more 
effective) relative to nicotine patch therapy, with incremental cost-effectiveness 
expressed in Swedish currency (6,600 SEK/QALY [men], 4,900 SEK/QALY [women]). 
Cornuz et al. used Markov modeling to simulate twin cohorts of one pack-a-day 
smokers in Switzerland to analyze cost-effectiveness of adding first-line smoking 
cessation therapies to counseling alone.83 The reference cohort was offered routine 
counseling at office visits; the other cohort received, in addition to initial counseling, an 
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offer for pharmacotherapy (gum, patch, spray, inhaler, bupropion). Smokers accepting 
pharmacotherapy received 5 additional follow-up consultations throughout treatment. 
The models used reference studies reporting point-prevalence abstinence at 12 months. A 
model was run for each of the five pharmacotherapies. Adding bupropion to counseling 
was most cost-effective, ranging from €1,768 to €3,646 (currency in euros), followed by 
the patch (€3,113 to €6,423), spray (€3,669 to €7,570), inhaler (€3,700 to €7,634), and 
then gum (€4,266 to €8,799).  
Cornuz published a follow-up study in 2006, updating estimates from Switzerland 
and adding data from Canada, France, Spain, United States, and United Kingdom.84 Twin 
cohorts were simulated for each country to assess the adjunct of first-line 
pharmacotherapies to counseling alone. Again, adding bupropion was most cost-effective 
for men and women, followed by patch, spray, gum, and inhaler. Incremental costs per 
life-year saved for men ranged from $792 in Canada to $1,934 in the U.S., $1,758 in 
Spain to $3,396 in United Kingdom, $1,935 in Spain to $5,275 in the U.S., $2,230 in 
Spain to $5,509 in the U.S., and $3,480 in Switzerland to $5,759 in France for bupropion, 
patch, spray, gum, and inhaler therapies, respectively.  Incremental costs per life-year 
saved for women ranged from $1,196 in Canada to $2,922 in the U.S., $2,657 in Spain to 
$5,131 in United Kingdom, $2,923 in Spain to $7,969 in the U.S., $3,370 in Spain to 
$7,643 in the U.S., and $5,257 in Switzerland to $8,700 in France for bupropion, patch, 
spray, gum, and inhaler therapies, respectively.    
Feenstra et al. analyzed cost-effectiveness of increased implementation of five 
face-to-face interventions (minimal counseling with and without NRT, intensive 
counseling with NRT or with bupropion, and telephone counseling) over current practice 
in the Netherlands.85 Using modeling techniques, the number of additional quitters and 
subsequent life-years and quality-adjusted life-years gained were estimated assuming 
increased implementation of interventions over 1, 10, and 75 years for each intervention. 
Researchers used available country data to estimate cessation, natural quit, and relapse 
rates as well as intervention costs. Minimal counseling as a strategy dominated current 
practice, as it was less costly and more effective (yielding 45 additional quits for $680 
less per 1000 smokers). Permanent increased implementation (75 years) yielded the most 
favorable results, with incremental costs of €1,400, €1,800, €4,300, and €6,200 per life-
year gained for telephone counseling, minimal counseling and NRT, intensive counseling 
and bupropion, and intensive counseling with NRT, respectively. Incremental costs per 
QALY were more attractive at €1,100, €1,400, €3,400, and €4,900 for the 
aforementioned therapies. 
Gilbert et al. estimated incremental cost-effectiveness of first-line 
pharmacotherapies over physician counseling alone in Seychelles to justify the provision 
of pharmacotherapies in developing countries.86 The authors used a model validated by 
Cornuz, simulating identical smoker cohorts that receive either physician counseling or a 
combination of counseling and pharmacotherapy. The model was run for each of five 
first-line pharmacotherapies. Adding bupropion was most cost-effective, followed by 
patch, gum, inhaler, and spray. This order differed from Cornuz’s findings mainly 
because of variations in drug prices across countries.  
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Wasley et al. explored cost-effectiveness of providing nicotine patch therapy as an 
adjunct to brief counseling.87 Using data from meta-analysis and other literature, 
incremental cost per life-year saved was calculated for identical cohorts of 400 U.S. 
pack-a-day smokers. Nicotine patch therapy was relatively cost-effective, ranging from 
$1,796 to $4,391 per life-year saved depending upon gender and age.  
Woolacott et al. used data from previous meta-analyses and cost-effectiveness 
analyses to assess incremental cost-effectiveness of adjunct smoking cessation strategies 
(nicotine replacement therapy, bupropion, and combination therapy) versus counseling 
only for the United Kingdom population.88 A decision model was developed to estimate 
costs and effects of the various strategies by cost per quit, cost per life-year saved, and 
cost per QALY. As seen with other studies, bupropion and counseling was the most cost-
effectiveness strategy, with ICERs of £1,278 per quit, £639 per life-year saved, and £473 
per QALY (currency in pounds). Nicotine replacement therapy and bupropion and 
counseling produced ICERs of £1,781 per quit, £890 per life-year saved, and £660 per 
QALY. Nicotine replacement therapy and counseling produced ICERs of £2,001 per quit, 
£1,000 per life-year saved, and £741 per QALY. 
Comparisons of Cost-Effectiveness 
Cost-effectiveness analyses of life-saving interventions are often displayed in 
league tables, which allow study results to be compared. Due to differences in 
perspective, setting (country), and cost-effectiveness outcomes, results of studies must 
first be equalized to allow for comparison. In order to achieve equivalence across studies, 
incremental cost-effectiveness estimates required conversion to current year dollars, 
using a historical exchange rate database for exchanging foreign currencies to the U.S. 
dollar and the consumer price index (CPI) to update estimates to the year 2009. The 
studies were separated by geography (U.S. versus international) and effect (cost per quit, 
life-year saved, QALY) to evaluate the ranges of incremental cost-effectiveness across 
studies. Tables 2-2 and 2-3 summarize cost-effectiveness of international and U.S. 
studies, respectively. 
Among international studies, smoking cessation interventions were extremely 
cost-effective, ranging from $768-$5,067/quit, $954-$11,601/LYS, and $1,008-
$8,872/QALY. U.S.-based interventions were equally cost-effective, ranging from $545-
$7,189/quit and $2,513-$6,019/LYS. These figures are small in comparison to the costs 
of other healthcare interventions; mammography screening or treatment for high 
cholesterol are $50,000 and $100,000/LYS, respectively.33 In 1995, Tengs and colleagues 
reviewed 500 life-saving interventions; overall, the median medical intervention cost 
$19,000 per life-year saved (or $27,228 in 2009 dollars).50 The cost-effectiveness of 
smoking cessation treatments is more evident when comparing incremental cost/QALY. 
Incremental costs for smoking cessation interventions are at most a tenth of the accepted 
threshold of $50,000/QALY.  
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Table 2-2. League Table of International Cost-Effectiveness Analyses of Smoking 
Cessation Interventions 
Author Intervention Cost ($, 2009) 
                   Cost/Quit  
Feenstra et al.  MC vs. Current Practice $768 
Woolacott et al. Counsel + Bupr vs. Counsel $2,723 
Feenstra et al.  TC vs. Current Practice $2,798 
Feenstra et al.  MC + NRT vs. Current Practice $2,986 
Woolacott et al. Counsel + NRT + Bupr vs. Counsel $3,795 
Feenstra et al.  IC + Bupr vs. Current Practice $4,112 
Woolacott et al. Counsel + NRT vs. Counsel $4,264 
Feenstra et al.  IC + NRT vs. Current Practice $5,067 
Cost/Life-Year Saved 
Feenstra et al.  MC vs. Current Practice cost-saving 
Cornuz et al. (2006) Counsel + Bupr vs. CO (Males) $954-$2,330 
Woolacott et al. Counsel + Bupr vs. Counsel $1,362 
Cornuz et al. (2006) Counsel + Bupr vs. CO (Females) $1,441-$3,520 
Gilbert et al.  Counsel + Bupr vs. CO (Males) $1,519-$2,014 
Woolacott et al. Counsel + NRT + Bupr vs. Counsel $1,896 
Cornuz et al. (2006) Counsel + Patch vs. CO (Males) $2,118-$4,091 
Woolacott et al. Counsel + NRT vs. Counsel $2,131 
Gilbert et al.  Counsel + Patch vs. CO (Males) $2,273-$3,013 
Cornuz et al. (2006) Counsel + Spray vs. CO (Males) $2,331-$6,354 
Gilbert et al.  Counsel + Bupr vs. CO (Females) $2,378-$3,264 
Feenstra et al.  TC vs. Current Practice $2,389-$2,316 
Cornuz et al. (2006) Counsel + Gum vs. CO (Males) $2,686-$6,094 
Cornuz et al. (2003) Counsel + Bupr vs. CO (Males) $2,935-$4,732 
Feenstra et al.  MC + NRT vs. Current Practice $3,071-$2,664 
Cornuz et al. (2006) Counsel + Patch vs. CO (Females) $3,200-$6,180 
Cornuz et al. (2006) Counsel + Spray vs. CO (Females) $3,521-$9,559 
Gilbert et al.  Counsel + Patch vs. CO (Females) $3,558-$4,883 
Cornuz et al. (2003) Counsel + Bupr vs. CO (Females) $3,562-$6,052 
Cornuz et al. (2006) Counsel + Gum vs. CO (Females) $4,059-$9,206 
Cornuz et al. (2006) Counsel + Inhaler vs. CO (Males) $4,192-$6,937 
Gilbert et al.  Counsel + Gum vs. CO (Males) $4,258-$5,643 
Gilbert et al.  Counsel + Inhaler vs. CO (Males) $4,922-$6,523 
Cornuz et al. (2003) Counsel + Patch vs. CO (Males) $5,167-$8,334 
Gilbert et al.  Counsel + Spray vs. CO (Males) $5,273-$6,989 
Cornuz et al. (2003) Counsel + Spray vs. CO (Males) $6,090-$9,823 
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Table 2-2. (continued) 
Author Intervention Cost ($, 2009) 
Cost/Life-Year Saved 
Cornuz et al. (2003) Counsel + Inhaler vs. CO (Males) $6,141-$9,906
Cornuz et al. (2003) Counsel + Patch vs. CO (Females) $6,272-$10,661
Cornuz et al. (2006) Counsel + Inhaler vs. CO (Females) $6,332-$10,479
Gilbert et al.  Counsel + Gum vs. CO (Females) $6,666-$9,147
Cornuz et al. (2003) Counsel + Gum vs. CO (Males) $7,081-$11,418
Feenstra et al.  IC + Bupr vs. Current Practice $7,336-$8,019
Cornuz et al. (2003) Counsel + Spray vs. CO (Females) $7,393-$12,565
Cornuz et al. (2003) Counsel + Inhaler vs. CO (Females) $7,456-$12,671
Gilbert et al.  Counsel + Inhaler vs. CO (Females) $7,705-$10,573
Gilbert et al.  Counsel + Spray vs. CO (Females) $8,255-$11,329
Cornuz et al. (2003) Counsel + Gum vs. CO (Females) $8,595-$14,605
Feenstra et al.  IC + NRT vs. Current Practice $10,578-$11,601
Cost/Quality-Adjusted Life-Year 
Bolin et al.  Bupr vs. Patch (Males) cost-saving
Bolin et al.  Bupr vs. Gum (Males) cost-saving
Feenstra et al.  MC vs. Current Practice cost-saving
Woolacott et al. Counsel + Bupr vs. Counsel $1,008
Woolacott et al. Counsel + NRT + Bupr vs. Counsel $1,406
Woolacott et al. Counsel + NRT vs. Counsel $1,579
Feenstra et al.  TC vs. Current Practice $1,877-$2,559
Feenstra et al.  MC + NRT vs. Current Practice $2,389-$2,900
Bolin et al.  Bupr vs. Patch (Females) $2,539
Bolin et al.  Bupr vs. Gum (Females) $4,054
Feenstra et al.  IC + Bupr vs. Current Practice $5,801-$6,142
Feenstra et al.  IC + NRT vs. Current Practice $8,360-$8,872
Abbreviations: Bupr: bupropion; CO: counsel only; IC: intensive counseling; MC: 
minimal counseling; NRT: nicotine replacement therapy; PI: psychological intervention; 
TC: telephone counseling. 
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Table 2-3. League Table of U.S. Cost-Effectiveness Analyses of Smoking Cessation 
Interventions 
Author Intervention Cost ($, 2009) 
Cost/Quit 
Hall et al.  MM + PI vs. MM $545 
Hall et al.  MM + Nortrip vs. MM $917 
Hall et al.  MM + Bupr vs. MM $1,868 
Barnett et al.  Stepped Care vs. Brief Intervention $7,189 
Cost/Life Year Saved 
Wasley et al.  Counsel + Patch vs. Counsel (Males) $2,513-$4,126 
Wasley et al.  Counsel + Patch vs. Counsel (Females) $4,253-$6,143 
Barnett et al.  Stepped Care vs. Brief Intervention $6,019 
Abbreviations: Bupr: bupropion; IC: intensive counseling; MM: medical management; 
Nortrip: nortriptyline; NRT: nicotine replacement therapy; PI: psychological intervention 
Recommendations for Conduct of Economic Evaluation 
While comparison of cost-effectiveness of smoking cessation programs, 
treatments, and services is highlighted in this review, the underlying methodology is of 
greater importance. Appropriate conduct of cost-effectiveness analysis in smoking 
cessation is necessary for achieving greater comparability across studies and is critical to 
designing the current analysis. Despite the existence of various guidelines addressing the 
design of economic evaluations, the recommendations from the U.S. Panel on Cost-
Effectiveness in Health and Medicine (The Panel) are widely cited and accepted as a 
specific rubric for designing and conducting cost-effectiveness analyses.80 The Panel 
outlines key elements for the appropriate conduct of economic evaluation. 
Perspective 
Perspective considers the point of view from which the study is designed. To 
frame the research question(s) from a particular perspective will determine which costs 
and consequences should be included. Costs and consequences will differ among 
patients, third-party payers, employers, or society, thus yielding varied estimates of cost-
effectiveness. The Panel recommends framing cost-effectiveness analyses from a societal 
perspective, to account for all costs and effects attributable to treatment, regardless of 
who experiences them. Among reviewed studies, those which utilized a third-party payer 
or governmental perspective represented health plans or countries with single-payer 
healthcare systems. A broader search of the literature produced only four studies 
published after the release of Panel guidelines framed from the societal perspective. A 
few articles provide cost-effectiveness results from multiple perspectives—this is a 
common and widely accepted approach, as it enhances homogeneity across studies. 
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Measures of Cessation 
Point prevalence abstinence was used as the measure of cessation in all studies 
reviewed. This reflects its wide acceptance as a cessation measure. Many articles 
specified 7-day point prevalence as the measure; in several studies, abstinence was 
verified biochemically. Biochemical verification is commonly conducted at follow-up to 
encourage valid self-report of abstinence, as various methods can detect nicotine 
exposure up to three days prior to follow-up. Velicer and colleagues contend that 
verification, though encouraged, is not necessary due to the rare nature of report 
falsification.89 Though the specifics of cessation measures fall outside of Panel 
recommendations, they are used to validate a quit, which is a common outcome measure 
used in cost-effectiveness studies of smoking cessation. 
Outcome Measures 
Outcome measures provide the basis for calculating cost-effectiveness ratios. 
These ratios are used to explain a program’s cost relative to achieving an effect. Outcome 
measures can be disease-specific or generic. In the smoking cessation literature, number 
of quits and life-years saved are more commonly used effects. These measures are 
preferred because they are easy to comprehend among healthcare decision makers. 
Among studies employing a societal perspective, cost per QALY is a standard, although 
cost per quit and cost per life-year saved are often reported as well. Panel 
recommendations encourage the use of a cost per QALY ratio, because it reflects the 
value to achieve both longer and more productive life. In addition, cost-effectiveness 
results should be reported as an incremental cost-effectiveness ratio, or the difference in 
costs for an intervention versus its comparator divided by the difference in their effects. 
None of the U.S. studies considered cost per QALY; only Barnett and Wasley’s studies 
extended their analyses to consider cost per life-year saved.77, 87 
Discounting 
The Panel, in their recommendations, strongly supports the use of discounting. It 
is necessary because costs and benefits in a study are not typically incurred within the 
same year. In many cases, both costs and benefits can occur over two different time 
horizons, thus necessitating discounting of costs and benefits. In a few cases, costs are 
incurred in one year, while only benefits occur across several years; here, only benefits 
should be discounted. A 3% discount rate should be applied to costs and effects as 
appropriate, as well as an alternative 5% rate. The suggested rate reflects current 
estimates of real economic growth, while the alternative rate accommodates comparison 
across older studies, which often used 5% as a discounting standard. Justifications for 
discounting were found in many studies; one such discussion is highlighted in the study 
by Feenstra and colleagues.85 In their simulation, discounting accounts for delayed 
accrual of health effects relative to the immediate accrual of intervention costs. Most 
studies cited a discount rate of 3%;82-84, 86 another used 5%.87 Abroad, countries have 
adopted alternate standards; the Dutch standard of 4% was noted in Feenstra’s study.85  In 
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the United Kingdom, a rate 3.5% is recommended,90 although Woolacott’s study used 
health effects discounted by 1.5%.88 
Use of Modeling 
Several studies utilize Markov modeling techniques to estimate, prospectively, 
cost-effectiveness of proposed programs.82-86 Prospective cost-effectiveness analysis with 
models can assist healthcare financing bodies in deciding whether it is beneficial or not to 
offer and even to cover certain smoking cessation products, services, or programs. Data 
extracted from clinical trials or other sources are used to estimate treatment course and 
duration, probabilities of success, and resulting risks and costs of adverse events 
(associated with treatment). Other literature sources are used to estimate physician time 
and costs for intervention, administrative costs of intervention, patient’s costs for 
transportation and lost work-time, and other appropriate costs (depending on the 
perspective used). Examples of costing techniques are detailed in Cornuz’s and Gilbert’s 
studies.83, 86 
Markov modeling and related techniques are beneficial for simulating future 
outcomes, which extend beyond the time horizon of the study or trial. These models 
typically use long-term cost-effectiveness measures, such as life-years saved or QALYs, 
to estimate long-term impacts of smoking cessation on morbidity and/or mortality. This 
technique can be used prospectively to provide justification for long-term investments in 
interventions to achieve greater cessation. While this may not be of great importance to 
health plans, which typically focus on short-term outcomes, it provides great value to 
healthcare systems that finance the healthcare of a population over the lifetime. 
Summary 
Studies evaluating cost-effectiveness of moderate to intense smoking cessation 
interventions may be underrepresented in this review. This is due in part to selection 
criteria used. Requirement of pharmacotherapy and counseling caused several studies 
involving pregnant smokers to be excluded. In addition, newer studies in smoking 
cessation are analyzing alternative intervention contact methods (via computer, mail, or 
telephone counseling/quit lines), which were not included. A significant number of cost-
effectiveness analyses conducted abroad were also excluded because they were published 
in foreign languages. A broader body of literature in economic evaluation of smoking 
cessation exists; many of these studies address alternative strategies: reimbursement of 
smoking cessation treatments, tobacco taxation and anti-smoking policies and campaigns. 
Still, this review provides a strong base for which STEP results can be compared. 
Among the studies reviewed here, only three were conducted in the United States 
and none of them comply with current recommendations outlined by the Panel. Given the 
expanded use of economic evaluations in healthcare to inform financing and clinical 
guidelines, studies must prove methodologically sound, clinically oriented, and policy 
relevant. The recent growth of cost-effectiveness literature in smoking cessation indicates 
wider acceptance of economic evaluation in the field. Conversely, as the characteristics 
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of the smoking population changes (more established, recalcitrant smokers), researchers 
will need to place increased emphasis on conducting and evaluating more moderate to 
intense interventions.91 Smokers today are more likely to be low-income, educated at a 
high school level or less, and minority. Without focused intervention in these vulnerable 
populations, where a paucity of research already exists, disparities will continue to 
persist.  
Conducting an economic evaluation for STEP is necessary for several reasons. 
First, it will build on literature evaluating cost-effectiveness of newer smoking cessation 
interventions. Fiore and colleagues have proposed further study of stepped care in 
smoking cessation; as yet, no formal recommendation for this or other tailored 
approaches has been made.33  In addition, conducting cost-effectiveness alongside a 
stepped care study is feasible and generally encouraged.79 Second, this study will adhere 
to standards recommended by the Panel. Economic evaluations conducted in the United 
States have consistently lacked a methodological standard, while the United Kingdom 
and other countries adhere to and enforce use of a single standard of conduct. Lastly, this 
evaluation is needed to justify future funding of tobacco control efforts, which must focus 
on the smoking population which remains. The underlying study is comprised of low-
income, minority smokers for which more research is needed to establish effectiveness 
and cost-effectiveness.  
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CHAPTER 3: METHODS 
Data Collection 
Data for the study was collected as part of the original research intervention, 
STEP. Data was collected at each visit from research participants via questionnaires and 
patient chart records. The data captured smoking status, nicotine dependency, and other 
statistics relevant to the study. Data from forms and charts were checked for 
completeness and accuracy before being entered into the system. Validation checks were 
run periodically to identify data errors. More specific details regarding data collection 
and management are described elsewhere. Data collected through June 2009 were 
cleaned and converted into a de-identified dataset for use in the cost-effectiveness 
analysis. Although requirements for human subjects training have been satisfied, the 
original dataset with patient identifiers was not accessed to avoid unwarranted 
identification of participants. Appropriate security measures were taken to ensure that 
data and related components were not breached. 
Sample Size 
A total of 406 participants from University of Tennessee Health Science Center 
(Memphis, Tennessee) and Mayo Clinic (Rochester, Minnesota) were enrolled in the 
smoking cessation study. As of June 2009, data for 319 completers were available for 
analysis; this included the full sample from Mayo Clinic (n=136) and a significant 
portion from UTHSC (183 of 270). Descriptive analyses were conducted to test the 
statistical equivalence of completers and the remaining UTHSC sample. The results of 
this analysis, shown in Table 3-1, reveal no differences in most factors. Estimates for 
both cost-effectiveness analysis and simulation of future events were based on completers 
at June 2009.  
Conducting Cost-Effectiveness Analysis 
As mentioned earlier, methodological standards for conducting cost-effectiveness 
analyses in medicine and health were released in 1996 by the U.S. Public Health 
Service’s Panel on Cost-Effectiveness in Health and Medicine.80 These standards have 
grounded the methodology of this analysis, using a reference case method. The Panel 
requires that cost-effectiveness analyses be conducted from the societal perspective, 
including all costs associated with disease and treatment as well as future costs averted by 
intervention. Additionally, the standards require use of cost-utility analysis (a specific 
subtype of cost-effectiveness analysis), where health-related quality of life measures are 
incorporating into cost-effectiveness ratios to produce a dollar cost per quality-adjusted 
life year (QALY) gained. In STEP, no measures are collected to evaluate health-related 
quality of life; further, the time horizon of the study (two years) is not adequate enough to 
assess long-term impacts of cessation on costs and quantity/quality of life. For purposes 
of this study, two analyses were conducted. First, the cost-effectiveness analysis of the  
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Table 3-1. Characteristics of Completers versus Remaining Participants 
  UTHSC  Mayo Clinic 
 Variable 
Stepped 
care 
sample    
(n=85) 
Stepped 
care 
others    
(n=43)  
Repeat 
sample   
(n=98) 
Repeat 
others 
(n=44)  
Repeat 
(n=70) 
Stepped 
care 
(n=66) 
Age, mean (SD) 44.1 
(9.7) 
44.7 
(11.1)
45.1 
(11.4)
46.4 
(9.7)
40.8 
(10.7) 
40.4 
(12.6)
Gender, n (%) 
Male 39 (46) 16 (37) 43 (44) 39 (46) 32 (46) 37 (56)
Female 46 (54) 27 (63) 55 (56) 46 (54) 38 (54) 29 (44)
Race/ethnicity, 
n (%) 
NHW 40 (47) 18 (42) 54 (55) 40 (47) 65 (93) 59 (89)
NHB 45 (53) 25 (58) 43 (44) 45 (53) 4 (6) 1 (2)
OTH 0 (0) 0 (0) 1 (1) 0 (0) 1 (1) 5 (9)
Fagerstrom 
score, mean 
(SD) 
5.91 
(2.2) 
5.11 
(2.2)
5.57 
(2.3)
5.68 
(2.3)
5.44 
(1.7) 
5.39 
(2.2)
CES-D score, 
mean (SD) 
10.07 
(6.9) 
6.84 
(6.6)a
9.88 
(7.3)
8.09 
(6.1)
8.70 
(6.1) 
6.35 
(5.8)b
CPD, mean 
(SD) 
23.0 
(11.6) 
20.7 
(8.8)
23.7 
(11.2)
23.5 
(9.5)
21.3 
(8.4) 
20.5 
(7.3)
CO, mean (SD) 
23.51 
(11.6) 
19.36 
(8.4)c  
23.36 
(12.2)
18.74 
(9.9)d  
22.70 
(9.8) 
22.22 
(10.9)
Note: Differences across UTHSC groups are noted by superscript letters. 
a Significant at p=0.01 
b Significant at p=0.02 
c Significant at p=0.01 
d Significant at p=0.03 
Abbreviations: CES-D: Center for Epidemiologic Studies Depression Scale; CO: carbon 
monoxide, CPD: cigarettes per day, NHB: non-Hispanic black, NHW: non-Hispanic 
white, OTH: other race, SD: standard deviation. 
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STEP study was conducted from an institutional perspective. Next, the simulation of 
future outcomes, which extends cost-effectiveness to the lifetime, encompassed a societal 
perspective. This exception is accepted by Gold; evaluation of cost-effectiveness from 
multiple perspectives is permitted, as long as one (the reference case analysis) is 
societal.80  
Study Design 
 A schematic of the STEP study is illustrated in Figure 3-1. As mentioned 
previously, patients received up to three opportunities to receive combined 
pharmacological and behavioral treatment. As baseline, eligible patients were 
randomized to stepped care or repeat care arms. They then received initial treatment 
(nicotine patch and one counseling session). Patients returned at six months, quit status 
was assessed, and appropriate treatment assigned. For example, a stepped care patient 
who relapsed at the six-month visit was stepped up to bupropion and four counseling 
sessions; a repeat care patient who relapsed at six months received nicotine patch therapy 
and one counseling session again. Patients who quit successfully did not receive 
intervention. A similar strategy was used for patients returning at twelve months. Patients 
could not receive treatment beyond the twelve month visit; quit status was assessed at 18 
months and at final follow-up (24 months). 
Calculation of Research Costs 
Since analysis took place alongside a research study, only direct medical and 
treatment costs borne by the research study were considered. Costs included were for 
pharmacotherapy, treatment and follow-up visits, counseling sessions, telephone follow-
up, and participant time lost in treatment. Any outside costs borne by patients to achieve 
and/or maintain cessation were not included. Indirect administrative costs were also 
excluded, as these data were not made available. Costs for pharmacotherapy reflect 
lowest retail costs; these were adjusted as necessary to reflect base year pricing. 
Treatment and follow-up visit costs were calculated using average visit time multiplied 
by the hourly wage(s) of the research personnel involved. Supplies used during the 
treatment visit were not considered (i.e. urinalysis and cotinine validation), as they were 
minimal and unlikely to differ between study arms. Costs of counseling were calculated 
by multiplying the research nurse’s hourly wage by the amount of time spent counseling. 
Telephone follow-up costs were calculated using time spent making telephone follow-up 
calls multiplied by the hourly wage of research personnel. Participants received 
reimbursement at each treatment and follow-up visit; these costs were summed to 
represent time lost in treatment. A separate cost for missed visits was assigned. Labor 
costs were sourced from the Bureau of Labor Statistics, using 2006 median estimates for 
registered nurse and medical assistant titles.92 Details of the cost calculations are outlined 
in Table 3-2. 
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 Figure 3-1. STEP Study Schematic 
Note: Shaded areas denote study periods (i.e. baseline, 6-month visit, etc.). 
Abbreviations: M: months; Maintain: maintenance phase; Step 1: nicotine patch plus 1 
counseling session; Step 2: bupropion plus 4 counseling sessions; Step 3: nicotine patch 
and gum plus 6 counseling sessions. 
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Table 3-2. Cost Calculations for STEP CEA 
Resource Units 
Unit 
cost Total Notes/Source 
Pharmacotherapy  
    Patch (Steps 1-3) 1 $85.97 $85.97 6 weeks Habitrol (2 weeks @ 
21, 14, 7mg) 
    Gum (pieces) 1680 $0.25 $424.84 Nicorette gum (12 ppd, 4 
weeks; 24 ppd, 8 weeks) 
    Patch + gum $510.81  
    Bupropion (150 mg) 123 $1.17 $143.47 AWP, 2006 RedBook 
  
Clinic visit  
    Technician time (hrs) 0.417 $12.64 $5.27 Technician costs to take labs, 
verify CO levels, height/weight 
(25 minutes) 
    Nurse time (hrs) 0.333 $27.54 $9.18 Nurse time for patient 
assessment (20 minutes) 
    Counselor time (hrs) 1 $27.54 $27.54 Counsel cost/session 
(Counselor: Research nurse) 
    Patient time lost in 1 $25.00 $25.00 Patient incentive for 
participation     treatment 
    Telephone follow-up 0.25 $12.64 $3.16 Staff time spent to assess quit 
status, provide support (15 
minutes) 
    (@7 wk) 
 
Total visit $70.15 Total visit cost: Items 2a-2d 
  
Step cost  
     Patch $156.12 Patch + Clinic visit 
     Bupropion $334.16 Bupropion + Clinic visit + 3 
additional counsel + 12 phone 
calls 
     Patch + gum $728.14 Patch + gum + Clinic visit + 5 
additional counsel + 3 phone 
calls 
Recycle cost (Patch) $156.12 Patch + Clinic visit 
  
Missed visit $9.48 Follow-up phone calls 
Maintain $45.77 Clinic visit + summary of 
progress (15 minute assessment) 
Follow-up $42.61 Clinic visit + summary of 
progress (15 minute assessment) 
Note: Costs not available for 2006 were adjusted accordingly, using the Consumer Price 
Index. 
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Measures and Validation of Cessation 
The underlying intervention relied on self-report of abstinence, with expired 
carbon monoxide readings as an auxiliary mechanism for validating point-prevalent 
cessation. Expired carbon monoxide measurements are captured by a small machine 
connected to a small disposable tube in which a participant exhales. This was performed 
at baseline and at each follow-up. If a participant reported abstinence but yielded an 
expired carbon monoxide reading beyond 10 parts-per-million (ppm), salivary cotinine 
measures were collected. Cotinine is a specific major metabolite of nicotine that can be 
detected in body fluids for 48 to 72 hours. It is considered the best biomarker for 
validating cessation. A self-reported abstainer with an unsatisfactory expired carbon 
monoxide reading (>10 ppm) and salivary cotinine level of 15 ng/mL or above was 
considered a continued smoker. This scenario is generally uncommon, as self-reports 
tend to be accurate with low false-negative rates.89 
Point-prevalent abstinence was used throughout the study to determine treatment 
paths. As mentioned above, point-prevalent abstinence was biochemically validated.  
Unacceptable carbon monoxide and salivary cotinine measures, despite self-report of 
abstinence, were considered treatment failure at each follow-up. Otherwise, failure was 
defined as smoking seven consecutive days or at least once a week on two consecutive 
weeks after the quit date, in accordance with recommendations.93 Continuous abstinence 
was used as the primary measure for end-of study-cessation; because it accounted for 
lapses, it could not be biochemically verified and was obtained via self-report. Point-
prevalence abstinence was used as a secondary end-of-study measure, as it was captured 
at each follow-up and used as a determinant of treatment. These measures were used in 
cost-effectiveness analysis to determine number of quitters in each treatment arm. 
Patients with complete observations were allocated costs on the basis of quit 
status at each visit, as it determined the treatment received. Patients missing data at any 
treatment or follow-up visit were assigned a cost equivalent to three follow-up calls. This 
cost represented time spent following up with patients who had missed a visit to 
encourage continued participation in the trial. End of study abstinence was determined by 
smoking status at the final follow-up visit. Patients missing data for this visit were 
assumed to be smoking at study end.  
Calculation of Cost-Effectiveness 
Considering the setting of the research study, the outcome of interest is a ratio of 
incremental cost per additional cessation achieved by stepped care relative to repeat care. 
The numerator of this ratio is the difference in costs in the stepped care arm relative to 
the repeat care arm, whereas the denominator captures the difference in the number of 
quitters. The ratio of cost differences to effect differences yields incremental cost-
effectiveness, or the cost to achieve one additional unit of effect. Whether the study is 
considered ‘cost-effective’ depends on both the ICER and a predetermined threshold. In 
the United States, no standard threshold for cost-effectiveness exists. For the purposes of 
this research, a threshold was set at $10,000/quit, to account for differences in treatment 
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time between short-term studies reviewed and STEP. Short-term studies were at most 
$5,067 per quit; a threshold of twice this amount was considered reasonable for 
establishing cost-effectiveness of STEP. A separate cost-effectiveness calculation as 
made for each type of quit (point-prevalence, continuous), as explained previously. All 
figures were adjusted to 2009 U.S. dollars. 
Discounting 
Time gaps between costs of intervention and realization of benefits exists when 
valuating cost-effectiveness of smoking cessation interventions. Typically the time 
horizon of the trial is too short to realize long-term outcomes of treatment. Discounting 
becomes necessary to calculate the present value of costs incurred and benefits achieved 
beyond the base year. As mentioned previously, Gold and colleagues recommend a 3% 
discount rate be applied to balance these differences in time.80 For this portion of the 
economic evaluation, discounting was applied only to costs incurred during year two of 
the study. Effects (number of quits) were not discounted. 
Simulating Future Health Outcomes 
The simulation model being used in the long-term analysis of smoking cessation 
considered lifetime effects of cessation on smoking-related morbidity and mortality and 
was adapted from Hoogenveen and Hurley.94, 95 Figure 3-2 depicts changes in the disease 
pathway that occurs as a result of cessation. In general, continued smoking leads to 
increased risk of morbidity and mortality resulting from smoking-related illnesses. For 
the purposes of this analysis, ischemic heart disease (including heart attack), 
cerebrovascular disease (including stroke), emphysema, lung cancer are modeled. Once 
tobacco-related disease is present, patients suffer decreased quality of life, increased 
healthcare expenditures and mortality risk. With timely intervention, a portion of current 
smokers will quit permanently. As a result, smoking-related disease can be averted, thus 
minimizing loss of quality of life, excess expenditures due to disease, and premature 
death.  
Model Structure and Parameters 
In order to model changes in smoking-related morbidity and mortality due to 
successful smoking cessation, a microsimulation model was constructed using TreeAge 
Pro Suite 2009 (TreeAge Software Inc., Williamstown, MA). Using TreeAge, simple or 
complex disease or decision processes can be modeled. A simulation model was chosen 
over a traditional Markov type to account for patient-level characteristics (i.e. gender, 
race, age, and smoking status) that would impact transitions through the model.   
Figure 3-3 illustrates the simulation model used for long-term cost-effectiveness 
analysis. The model includes five health states; state numbers indicate progression of 
disease while state letters denote smoking status. Patients enter the model in state 1A or 
1B, based on end-of-study smoking status. (The model assumes that, at entry, no one has 
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 Figure 3-2. Change in Disease Pathway with Successful Cessation 
Sources: Hoogenveen RT, van Baal PH, Boshuizen HC, Feenstra TL. Dynamic effects of 
smoking cessation on disease incidence, mortality and quality of life: The role of time 
since cessation. Cost Eff Resour Alloc. 2008 January 11; 6:1.94 
Hurley SF, Matthews JP. The Quit Benefits Model: a Markov model for assessing the 
health benefits and health care cost savings of quitting smoking. Cost Eff Resour Alloc. 
2007 January 23; 5:2.95 
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Figure 3-3. Long-Term Outcomes Simulation Model 
Note: Stages 2A and 2B were partially collapsed to allow text to be readable at 100%. 
Stages 1A and 2A are identical in structure, as are stages 1B and 2B. 
Abbreviations: CBD: cerebrovascular disease, CSND: current smoker no disease, 
CSWD: current smoker with disease, EMP: emphysema, FSND: former smoker no 
disease, FSWD: former smoker with disease, IHD: ischemic heart disease, LC: lung 
cancer.  
Source: TreeAge Pro Suite 2009 (TreeAge Software Inc., Williamstown, MA). 
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heart disease, COPD, or lung cancer.) These states are somewhat parallel, because until 
disease is acquired, smoking status will influence movement across them. However, 
patients in state 1B (current smoker, no disease) are more likely than those in 1A to either 
acquire disease or die, progressing to the next appropriate state (current smoker with 
disease or death). Only forward movement is allowed in the model; once a patient has 
disease, he cannot move backward to a non-diseased state. Likewise, once a patient 
moves to state 3 (death), they remain in that state until the model terminates. During each 
cycle, changes in smoking status, morbidity and mortality risks, annual treatment costs, 
and rewards (life-years or QALYs) are calculated.  At the end of each cycle, survival, 
smoking and disease statuses determined state transitions.  
Smoking-Related Mortality 
At the beginning of each cycle, mortality risk was assessed. During the first cycle, 
mortality risk was conditional on race-, gender-, and age-specific risk of death from other 
causes (not including death from smoking-related diseases being modeled). In subsequent 
cycles, mortality risk was contingent upon race, age, gender, risk of background death, 
and presence of smoking-related diseases. Because death can occur at any time during a 
cycle (year), it was expected that patients dying during a cycle would incur some 
healthcare costs. As a result, the model assesses one-half of the expenditures that would 
have been incurred without changes in disease or smoking status. So, if a patient entered 
the cycle as a former smoker with no disease, one-half the annual expenditures for a 
former smoker of his current age without disease would be assessed at death. Mortality 
rates were sourced from the 2006 Compressed Mortality File using CDC WONDER, an 
interactive database tool that houses public-use data on mortality, cancer incidence, HIV 
and AIDS, etc.96 The system was queried first for deaths from all causes, and separately 
for any deaths with cerebrovascular disease, ischemic heart disease, lung cancer, or 
emphysema as an underlying cause. Here, underlying cause identifies the disease or 
injury which initiated the train of events leading directly to death and would not include 
deaths due to injury among persons with the above-listed disease. Multiple-decrement life 
tables were created for each race-gender group, rendering age-specific probabilities of 
mortality from background causes and presence of smoking-related diseases, shown in 
Table 3-3. Life tables methods were sourced from Anderson.97 A patient’s risk of death 
was expressed as a summed probability of mortality (MR) conditional on race, age, 
gender (RAG) and presence of smoking-related diseases (1=present, 0=absent), as shown 
in Equation 3-1: 
MR(Background causes) = MR(All causes|RAG) – MR(Lung cancer|RAG) – MR(Emphysema|RAG) – 
MR(Cerebrovascular|RAG) – MR(Ischemic|RAG) 
MR(Patient) = MR(Background causes|RAG) + MR(Lung cancer|RAG)*(1/0) + MR(Emphysema|RAG)*(1/0) + 
MR(Cerebrovascular|RAG)*(1/0) + MR(Ischemic|RAG)*(1/0)  
(Eq 3-1) 
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Table 3-3. Mortality Rates by Age, Race, and Gender 
      NHW  NHB  OTH 
Cause Age group   M F  M F  M F 
BC 15-24 years 0.0183 0.0064 0.0377 0.0123 0.0343 0.0164
25-34 years 0.0202 0.0080 0.0478 0.0226 0.0389 0.0232
35-44 years 0.0367 0.0195 0.0725 0.0513 0.0587 0.0419
45-54 years 0.0688 0.0391 0.1378 0.0942 0.0961 0.0772
55-64 years 0.0978 0.0635 0.1729 0.1184 0.1320 0.1077
65-74 years 0.1644 0.1135 0.2457 0.1774 0.1913 0.1737
75-84 years 0.3677 0.2858 0.4208 0.3304 0.3641 0.3286
85+ years 0.3074 0.2516 0.3229 0.2539 0.3048 0.2406
IHD 15-24 years 0.0001 0.0000 0.0003 0.0001 0.0001 0.0002
25-34 years 0.0006 0.0002 0.0013 0.0006 0.0017 0.0002
35-44 years 0.0046 0.0012 0.0067 0.0036 0.0063 0.0013
45-54 years 0.0168 0.0042 0.0270 0.0127 0.0208 0.0061
55-64 years 0.0332 0.0106 0.0492 0.0249 0.0383 0.0145
65-74 years 0.0570 0.0252 0.0787 0.0481 0.0642 0.0399
75-84 years 0.1314 0.0801 0.1306 0.1030 0.1250 0.0979
85+ years 0.1183 0.0910 0.1027 0.0897 0.1140 0.0941
CBD 15-24 years 0.0001 0.0001 0.0002 0.0001 0.0001 0.0003
25-34 years 0.0002 0.0002 0.0006 0.0007 0.0003 0.0005
35-44 years 0.0009 0.0007 0.0027 0.0027 0.0021 0.0020
45-54 years 0.0025 0.0018 0.0089 0.0073 0.0082 0.0056
55-64 years 0.0050 0.0035 0.0152 0.0099 0.0113 0.0100
65-74 years 0.0124 0.0092 0.0256 0.0192 0.0229 0.0211
75-84 years 0.0375 0.0358 0.0482 0.0473 0.0536 0.0591
85+ years 0.0358 0.0382 0.0354 0.0385 0.0449 0.0459
EMP 15-24 years 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000
25-34 years 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000
35-44 years 0.0000 0.0000 0.0001 0.0000 0.0002 0.0000
45-54 years 0.0002 0.0002 0.0005 0.0002 0.0001 0.0002
55-64 years 0.0011 0.0008 0.0011 0.0005 0.0007 0.0005
65-74 years 0.0032 0.0022 0.0023 0.0009 0.0023 0.0011
75-84 years 0.0057 0.0039 0.0038 0.0016 0.0041 0.0014
85+ years 0.0026 0.0013 0.0021 0.0005 0.0018 0.0007
LC 15-24 years 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000
25-34 years 0.0001 0.0000 0.0001 0.0001 0.0003 0.0001
35-44 years 0.0010 0.0009 0.0018 0.0015 0.0022 0.0011
45-54 years 0.0062 0.0042 0.0120 0.0065 0.0080 0.0060
55-64 years 0.0187 0.0116 0.0281 0.0132 0.0182 0.0122
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Table 3-3. (continued) 
      NHW  NHB  OTH 
Cause Age group   M F  M F  M F 
LC 65-74 years 0.0359 0.0212 0.0425 0.0209 0.0380 0.0250
75-84 years 0.0482 0.0274 0.0522 0.0247 0.0483 0.0263
  85+ years   0.0150 0.0066  0.0160 0.0059  0.0136 0.0072
Notes: Estimates were truncated to the fourth decimal place to fit the page.  
Deaths from diseases were identified by ICD-10 codes or groups: Ischemic heart disease 
(ICD-10: I20-I25), Cerebrovascular disease (ICD-10: GR113-070), Emphysema (ICD-
10:  GR113-084), Lung cancer (ICD-10: GR113-027). 
Abbreviations: BC: background causes, CBD: cerebrovascular disease, EMP: 
emphysema, F: female, IHD: ischemic heart disease, LC: lung cancer, M: male, NHB: 
non-Hispanic black, NHW: non-Hispanic white, OTH: other race. 
Source: Centers for Disease Control and Prevention, National Center for Health 
Statistics. Compressed Mortality File 1999-2006. CDC WONDER Online Database, 
compiled from Compressed Mortality File 1999-2006 Series 20 No. 2L, 2009. Accessed 
at http://wonder.cdc.gov/cmf-icd10.html on August 19, 2009.99 
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Smoking-Related Disease 
For patients surviving in a cycle, risk of acquiring smoking-related disease was 
assessed. As mentioned previously, patients’ risk of developing lung cancer, emphysema, 
cerebrovascular disease, and ischemic heart disease was modeled. Data from the National 
Health and Nutrition Examination Survey (NHANES) for years 2001-2006 were pooled 
to estimate incidence of the above-mentioned smoking-related diseases.98 Data from the 
smoking, demographic, and medical conditions modules for the 2001-02, 2003-04, and 
2005-06 NHANES cycles were merged by cycle, then resorted by SDMVSTRA and 
SDMVPSU variables and combined into a single dataset.  The dataset was queried to 
identify incident cases of the four smoking-related diseases among never, former, current 
smokers by race, gender, and age (18-34 years, 35-64 years, and 65 years and above). 
Prevalent cases of ischemic heart disease were identified by a positive response to one of 
two questions (positive diagnosis of coronary heart disease or previous heart attack). 
Prevalent cases of stroke, emphysema, and lung cancer were identified similarly, denoted 
by positive response to questions regarding physician diagnosis of disease. Time since 
diagnosis for smoking-related diseases was calculated by subtracting the survey 
respondent’s age at diagnosis from age when interviewed. Prevalent cases with a time to 
diagnosis of 0 and half of cases with a time to diagnosis of 1 were identified as incident 
cases in the absence of specific dates of birth, diagnosis, and interview. Incidence 
estimates were calculated using larger age group intervals than before to generate more 
reliable estimates across race and smoking status. Several studies indicate that risk of 
cardiovascular disease among former smokers and never smokers is equal after about 10 
years, while rates of emphysema and lung cancer remain elevated among former 
smokers. Since data were not robust enough to evaluate this trend, the appropriate 
incidence probabilities for never smokers were re- assigned to former smokers achieving 
abstinence beyond 10 years. In certain cases, incident cases were too low to provided 
estimates for specified cage groups and were combined to provide a single estimate for 
incidence risk. Table 3-4 summarizes the incidence probabilities generated for analysis. 
Cessation and Relapse 
Risk of relapse remains for quitters, although this probability decreases as a 
function of time spent abstinent. The longer a quitter remains a former smoker, the less 
likely they are to relapse in the future. To account for time since cessation, a tracker 
variable was created in TreeAge to count the number of continuous cycles spent in as a 
former smoker. The number of continuous cycles coincided with number of years of 
abstinence. The model assigned a probability of relapse, using published relapse rates for 
two to four years post cessation,100, 101 and interpolated rates for years 5 and beyond. 
Current smokers who made a successful quit attempt during a cycle transitioned to a 
former smoker, while those who were unsuccessful remained as current smokers. 
Likewise, a former smoker that relapsed during a cycle would become a current smoker 
in the next, while those who remained abstinent would continue the next cycle as a 
former smoker. Here, the model assumed that any future quit attempts would be unaided, 
since results from a recent NHIS survey suggested that most smokers quit in this fashion. 
So, the model assigned a quit probability equivalent to 12 month abstinence for an 
unaided quit attempt.102  
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Table 3-4. Incidence Rates for Smoking-Related Diseases 
NHW  NHB OTH 
Disease Status Age group  E SE  E SE   E SE 
IHD Current 18-34 years 0.000 0.000 0.000 0.000 0.003 0.003
35-64 years 0.010 0.004 0.010 0.005 0.007 0.005
65+ years 0.005 0.004 0.010 0.005 0.005 0.004
Former 18-34 years 0.000 0.000 0.000 0.000 0.000 0.000
35-64 years 0.011 0.004 0.015 0.008 0.010 0.005
65+ years 0.029 0.004 0.022 0.007 0.018 0.014
Never 18-34 years 0.000 0.000 0.002 0.002 0.000 0.000
35-64 years 0.008 0.002 0.003 0.002 0.002 0.001
65+ years 0.026 0.005 0.029 0.011 0.026 0.017
CBD Current 18-34 years 0.000 0.000 0.000 0.000 0.009 0.007
35-64 years 0.005 0.002 0.002 0.002 0.010 0.007
65+ years 0.006 0.005 0.009 0.010 0.008 0.003
Former 18-34 years 0.000 0.000 0.000 0.000 0.000 0.000
35-64 years 0.003 0.000 0.006 0.004 0.003 0.002
65+ years 0.018 0.004 0.035 0.017 0.016 0.007
Never 18-34 years 0.000 0.000 0.000 0.000 0.000 0.000
35-64 years 0.002 0.001 0.008 0.003 0.006 0.003
65+ years 0.019 0.004 0.040 0.013 0.012 0.007
EMP Current 18-34 years 0.004 0.003 0.000 0.000 0.005 0.005
35-64 years 0.008 0.002 0.001 0.001 0.015 0.010
65+ years 0.030 0.014 0.001 0.001 0.003 0.003
Former 18-34 years 0.000 0.000 0.000 0.000 0.000 0.000
35-64 years 0.002 0.001 0.003 0.003 0.000 0.000
65+ years 0.011 0.004 0.006 0.006 0.003 0.004
Never 18-34 years 0.000 0.000 0.000 0.000 0.000 0.000
35-64 years 0.001 0.001 0.000 0.000 0.001 0.001
65+ years 0.002 0.001 0.000 0.000 0.002 0.002
LC Current 18-34 years 0.000 0.000 0.000 0.000 0.000 0.000
35-64 years 0.000 0.000 0.000 0.000 0.000 0.000
65+ years 0.000 0.000 0.000 0.000 0.000 0.000
Former 18-34 years 0.000 0.000 0.049 0.034 0.000 0.000
35-64 years 0.002 0.001 0.005 0.002 0.000 0.000
65+ years 0.008 0.003 0.005 0.002 0.000 0.000
Never 18-34 years 0.000 0.000 0.000 0.000 0.000 0.000
35-64 years 0.000 0.000 0.000 0.000 0.000 0.000
    65+ years  0.000 0.000  0.000 0.000   0.000 0.000
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Table 3-4. (continued) 
Note:  Estimates were truncated to the third decimal place to fit on the page. In certain 
cases, no incidences of smoking-related diseases were reported; so rates were set to zero. 
Abbreviations: CBD: cerebrovascular disease, EMP: emphysema, E: estimate, IHD: 
ischemic heart disease, LC: lung cancer, M: male, NHB: non-Hispanic black, NHW: non-
Hispanic white, OTH: other race, SE: standard error. 
Source: Centers for Disease Control and Prevention (CDC). National Center for Health 
Statistics (NCHS). National Health and Nutrition Examination Survey Data. Hyattsville, 
MD: U.S. Department of Health and Human Services, Centers for Disease Control and 
Prevention, 2000-2006. Accessed online at: http://www.cdc.gov/nchs/nhanes.htm on 
August 19, 2009.98 
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Healthcare Costs 
Data from the 2006 Medical Expenditure Panel Survey (MEPS) were used to 
calculate relevant annual healthcare expenditures for patients dependent on age and 
presence of smoking-related diseases.103 Household component and medical conditions 
files were sorted by an identifier variable, DUPERSID, and merged to provide data on 
health expenditures resulting from smoking-related diseases. Medical conditions were 
identified by three-digit ICD-9 diagnosis codes and broader Clinical Classifications 
System (CCS) categories, which combine ICD-9 codes into more clinically relevant 
classes for easier analysis. CCS codes were used to denote observations recording 
expenditures due to lung cancer (CCS: 19), emphysema (CCS: 127), ischemic heart 
(CCS: 100,101) and cerebrovascular diseases (CCS: 109-113). The total expenditure 
variable, TOTEXP06, was fit to a regression equation, adjusting for age, gender, smoking 
status, and presence of the four smoking-related diseases. From the regression equation, 
gender- and age group-specific total expenditure and excess cost estimates for each 
disease were calculated.  
Quality-Adjusted Life Years (QALYs) 
Health-related quality of life (HRQL) scores were also estimated from the MEPS 
dataset used to calculate annual healthcare costs.103 In MEPS, several measures of health 
status are collected annually, including the Short Form-12 (SF-12) health survey. Despite 
its wide acceptance and application in health state evaluation, the SF-12 is limited in its 
ability to provide only HRQL measures. It cannot rate patient preferences for specific 
health states. Gold and colleagues recommend use of multi-attribute health status 
classification systems (MAHSCS), which use time trade-off or standard gamble 
techniques to elicit valuations of HRQL and preferences for other health states.79 These 
preferences are converted into utility scores that can be used in cost-effectiveness 
analysis. In the absence of these measures, mapping methods have been utilized to 
approximate MAHSCS scores from other health status surveys. Sullivan and Ghushchyan 
developed and validated a mapping algorithm to estimate EQ-5D scores from SF-12 
measures using scores collected previously in MEPS.104 This algorithm was applied to 
approximate EQ-5D scores from the SF-12 measures. In addition, these values were 
modeled in ordinary least squares (OLS) regression, controlling for CCS codes, 
demographic variables (age, gender), smoking status, and survey weights to generate 
coefficients representing decrement(s) in utility resulting from smoking and smoking-
related disease(s). Table 3-5 illustrates age-specific annual healthcare costs and utility 
weights used in analysis. Table 3-6 displays regression coefficients used to estimate 
changes in annual costs and utilities due to smoking and smoking-related diseases. 
Calculation of Cost-Effectiveness 
Considering a societal perspective, the simulation model produced long-term cost-
effectiveness of STEP or the ratio of lifetime costs and effects among patients after 
intervention in the study. TreeAge models were rerun assuming that all participants were 
smokers to determine changes in lifetime healthcare costs, cases of smoking-related  
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Table 3-5. Annual Healthcare Costs and Utilities Estimates 
Costs Utilitiesa 
Gender Age group AACb SE AAUc SE 
Female 18-24 years $1,383.27 361.95 0.9755 0.004 
25-34 years $2,694.59 412.36 0.9531 0.005 
35-44 years $4,005.91 462.77 0.9307 0.006 
45-54 years $5,317.23 513.19 0.9084 0.006 
55-64 years $6,628.54 563.60 0.8860 0.007 
65-74 years $7,939.86 614.01 0.8637 0.007 
75-84 years $9,251.18 664.42 0.8413 0.008 
85+ years $10,562.49 714.83 0.8189 0.008 
Male 18-24 years $589.12 544.36 0.9912 0.006 
25-34 years $1,900.44 594.77 0.9688 0.007 
35-44 years $3,211.75 645.18 0.9465 0.007 
45-54 years $4,523.07 695.59 0.9241 0.008 
55-64 years $5,834.39 746.00 0.9017 0.008 
65-74 years $7,145.70 796.41 0.8794 0.009 
75-84 years $8,457.02 846.82 0.8570 0.009 
85+ years $9,768.34 897.23 0.8346 0.010 
Note: Estimates listed approximate annual costs and HRQL utilities for former smokers 
without disease. 
a A mapping algorithm used to approximate EQ-5D scores from SF-12:   EQ-5D= 
0.057867 + 0.010367*PCS42 + 0.00822*MCS42 - 0.000034*PCS42*MCS42 - 0.01067 
b,c Total healthcare costs and EQ-5D scores were adjusted for age, gender, smoking 
status, and presence of smoking-related diseases 
Abbreviations: AAC: adjusted average cost, AAU: adjusted average utility, SE: standard 
error 
Sources: Center for Financing, Access, and Cost Trends, Agency for Healthcare Research 
and Quality. Medical Expenditure Panel Survey, 2006103 
Sullivan PW, Ghushchyan V. Mapping the EQ-5D index from the SF-12: US general 
population preferences in a nationally representative sample. Med Decis Making 2006 
July-August; 26(4):401-9.104 
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Table 3-6. Changes in Costs and Utilities with Smoking/SR Disease 
Costs  Utilities 
Smoking/SR disease Δ(AAC)a SE  Δ(AAU)b SE 
Current smoker -$284.66 191.84 -0.03468 0.002794
Ischemic heart disease $4,533.64 1016.23 -0.04821 0.01296
Cerebrovascular disease $5,133.11 1192.85 -0.06138 0.016126
Emphysema -$595.31 268.29 -0.00671 0.004633
Lung cancer $6,171.13 3197.38 -0.12297 0.029451
Note: Estimates listed represent increments/decrements to costs and utilities when 
smoking and/or smoking-related disease is present.  
a,b Changes in costs, utilities expressed in natural units (dollars, QALYs). 
Abbreviations: Δ(AAC): change in adjusted average cost, Δ(AAU): change in adjusted 
average utility, SE: standard error, SR: smoking-related. 
Source: Center for Financing, Access, and Cost Trends, Agency for Healthcare Research 
and Quality. Medical Expenditure Panel Survey, 2006103 
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disease, QALYs and survival due to successful cessation. The costs and effects yielded 
were subtracted from costs and effects in the initial model to calculate a ratio of 
incremental costs per quality-adjusted life-year (QALY) gained by successful cessation 
relative to unsuccessful cessation. The method of cessation (via stepped care or repeat 
care) is no longer of immediate importance; that successful cessation occurred is more 
relevant for examining future outcomes. The numerator of this ratio is the difference in 
future costs incurred by successful quitters relative to unsuccessful quitters, whereas the 
denominator captures the difference in the number of QALYs gained. The ratio of cost 
differences to effect differences yields incremental cost-effectiveness, or the cost to 
achieve one additional unit of effect. All figures were expressed in year 2009 U.S. 
dollars.  
Discounting 
As aforementioned, Gold and colleagues recommend a 3% discount rate to balance time 
gaps between costs of intervention and realization of benefits.80 For the extended 
economic evaluation, discounting was applied to costs incurred and QALYs gained 
beyond the base year (2009).   
Sensitivity Analysis 
 Certain model parameters were assigned lower and upper values to account for 
uncertainty around the model estimates; these values were used in sensitivity analysis. 
Parameters were set for unaided cessation, disease incidence, and mortality rates as well 
as annual healthcare costs and utilities, using calculated 95% confidence interval values 
or published ranges from the literature (unaided cessation). One-way and probabilistic 
sensitivity analyses (PSA) were conducted to evaluate impact of changes in disease 
incidence, mortality, unaided cessation, costs, and utilities on outcomes. A uniform 
distribution was applied to parameter values to equally select a range between lower and 
upper limit values. PSA generated average, minimum, maximum, and standard deviation 
values for costs and effects for treatment and comparator groups. The results of the 
original simulation were stored and re-run substituting discount rates of 0% and 5%. 
Comparing Results to Cost-Effectiveness Literature 
Results of short-term and long-term analyses were compared to studies reviewed 
in Chapter 2 to determine where STEP analyses fall in terms of cost-effectiveness. Cost-
effectiveness of the STEP study was compared to other short-term studies using cost per 
quit as a measure. Results of the future outcomes simulation were compared to long-term 
studies, both U.S. and international, that measured cost per QALY.  
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CHAPTER 4: RESULTS 
Cost-Effectiveness: STEP Study 
Characteristics of the STEP study sample are outlined in Table 4-1. Overall and 
by site, study arms were statistically equivalent. One exception was in the Mayo sample; 
a statistically significant difference in CES-D scores was observed. UTHSC participants 
were older and more racially diverse; in addition, they had higher depression scale and 
nicotine dependence scores, carbon monoxide readings, and smoked more cigarettes than 
Mayo Clinic counterparts. Only age and race differences were statistically significant. 
Study participation rates were relatively average; these details are noted in Table 4-2. 
Nearly 65% of study participants attended all treatment and follow-up visits; another 9% 
attended all but one visit. The majority of patients attending all sessions were from 
UTHSC, with 87% of participants remaining active (versus 34% of Mayo patients) 
throughout the study. Among Mayo patients, those randomized to stepped care attended 
more sessions than patients assigned to repeat intervention. This trend was similar in the 
UTHSC sample. Most STEP participants were available for final follow-up (n=229); the 
remainder were assumed to be smoking. Point-prevalence abstinence was confirmed in 
67 participants; 41 of these patients also reported continuous abstinence at end of study 
follow-up. Among those quitting, all but five reported to each treatment and follow-up 
visit. 
Table 4-3 reports costs, effects, and cost-effectiveness estimates for the entire 
sample and by site. Stepped intervention was more costly than repeat care in every 
scenario. Mean costs (per patient) were $875.09, $617.09, and $1,075.40 for overall, 
Mayo Clinic, and University of Tennessee Health Science Center (UTHSC) samples, 
respectively. All figures are expressed in 2009 U.S. dollars. Repeat costs were $422.26, 
$332.55, and $486.34 for the respective samples. Point-prevalence abstinence was 
reported and validated among 20.5% (versus 22.6%) of stepped care patients overall; 
among Mayo and UTHSC samples, 22.7% (versus 22.9%) and 18.8% (versus 22.5%) 
reported quitting. Continuous abstinence was reported among 11.9% (versus 14.3%), 
16.7% (versus 15.7%) and 8.2% (versus 13.3%) of stepped care patients overall, at Mayo, 
and at UTHSC, respectively. Because effectiveness results favored repeated intervention 
rather than stepped care, an ICER could not be calculated for the overall sample. Stepped 
care was dominated by repeat care; it was more costly and less effective. Among Mayo 
participants, stepped care was more costly and more effective, producing and incremental 
cost effectiveness estimate of $29,640 (continuous) per quit. This trend was opposite 
among patients at UTHSC, where repeat care was dominant. 
Differences in effectiveness by gender are reported in Tables 4-4 and 4-5. 
Overall, higher rates of point-prevalence and continuous abstinence were reported among 
men. Nearly 27% of men in the repeat intervention achieved point-prevalence abstinence 
at study end compared to only 19% of women. Quit rates among men and women in 
stepped care were similar, at 20% and 21%, respectively. Continuous abstinence was 
reported in 13% and 11% of men and women in the stepped care arm and in 19% and 
11% of men and women in the repeat intervention. Stepped care costs for women (versus 
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Table 4-1. Characteristics of STEP Study Sample 
Overall UTHSC (sample) Mayo 
 Variables 
Repeat 
(n=167) 
Stepped 
care 
(n=151)  
Repeat 
(n=98) 
Stepped 
care 
(n=85)  
Repeat 
(n=70) 
Stepped 
care 
(n=66) 
Age, mean 
(SD) 
43.3 
(11.3) 
42.4 
(11.1) 
45.1 
(11.4) 
44.1 
(9.7) 
40.8 
(10.7) 
40.4 
(12.6) 
Gender, n (%) 
Male 75 (45) 76 (50) 43 (44) 39 (46) 32 (46) 37 (56) 
Female 93 (55) 75 (50) 55 (56) 46 (54) 38 (54) 29 (44) 
Race, n (%) 
NHW 119 (71) 99 (66) 54 (55) 40 (47) 65 (93) 59 (89) 
NHB 47 (28) 46 (30) 43 (44) 45 (53) 4 (6) 1 (2) 
OTH 2 (1) 5 (4) 1 (1) 0 (0) 1 (1) 5 (9) 
Fagerstrom, 
mean (SD) 
5.52 
(2.0) 
5.68 
(2.2) 
5.57 
(2.3) 
5.91 
(2.2) 
5.44 
(1.7) 
5.39 
(2.2) 
CES-D, mean 
(SD) 
9.39 
(6.9) 
8.44 
(6.7) 
9.88 
(7.3) 
10.07 
(6.9) 
8.70 
(6.1) 
6.35 
(5.8)a 
CPD, mean 
(SD) 
22.7 
(10.2) 
21.9 
(10.0) 
23.7 
(11.2) 
23.0 
(11.6) 
21.3 
(8.4) 
20.5 
(7.3) 
CO, mean 
(SD) 
22.12 
(11.4) 
21.80 
(11.4) 
23.36 
(12.2) 
23.51 
(11.6) 
22.70 
(9.8) 
22.22 
(10.9) 
Note: UTHSC sample includes study completers as of May 31, 2009. 
a Statistically significant at p=0.03 
Abbreviations: CO: carbon monoxide, CES-D: Centers for Epidemiologic Studies 
Depression Scale, CPD: cigarettes per day (number), NHB: non-Hispanic black, NHW: 
non-Hispanic white, OTH: other race, UTHSC: University of Tennessee Health Science 
Center. 
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Table 4-2. STEP Study Outcomes 
    Participants   Quitters 
Overall Mayo UTHSC PPA CA 
Outcomes A S R  S R  S R   A A 
Visits 
attended 
(%) 
1 47 
(15) 
16 
(11) 
31 
(18)
16 
(24)
30 
(43)
0 (0) 1 (0)  - - 
2 21 
(7) 
14 
(9) 
7 (4) 14 
(21)
5 (7) 0 (0) 2 (2)  - - 
3 16 
(5) 
6 
(4) 
10 
(6)
4 
(6)
9 
(13)
2 (2) 1 (1)  - - 
4 30 
(9) 
11 
(7) 
19 
(12)
5 
(8)
7 
(10)
6  
(7)
12 
(12) 
 5  
(7) 
5 
(12)
5 205 
(64) 
104 
(69) 
101 
(60)
27 
(41)
19 
(27)
77 
(91)
82 
(84) 
 62 
(93) 
36 
(88)
Total 319 151 168 66 70 85 98  67 41
Therapy 
(%) 
2 205 
(64) 
106 
(70) 
99 
(59)
34 
(52)
29 
(41)
72 
(73)
70 
(82) 
 - - 
3 179 
(56) 
89 
(59) 
90 
(54)
19 
(29)
18 
(26)
70 
(71)
72 
(84) 
 - - 
Quits, (%)    
PPA 67 
(21) 
31 
(21) 
38 
(23)
15 
(23)
16 
(23)
16 
(19)
22 
(22) 
 - - 
CA 41 
(13) 
18 
(12) 
24 
(14)  
11 
(17)
11 
(16)  7 (8)
13 
(12) 
 - - 
Abbreviations: A: all, CA: continuous abstinence, PPA: point-prevalence abstinence, R: 
repeat care, S: stepped care, UTHSC: University of Tennessee Health Science Center. 
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Table 4-3. Cost-Effectiveness Results, Overall and by Site 
All Mayo UTHSC 
Variable Arm Mean SE Mean SE Mean SE 
Costs S $875.09 $36.60 $617.09 $51.20 $1,075.40 $39.76
R $422.26 $10.53 $332.55 $16.73 $486.34 $9.14
Diff $452.83 $284.54 $589.06 
PPA S 0.2053 0.033 0.2273 0.052 0.1882 0.043
R 0.2262 0.032 0.2286 0.051 0.2245 0.042
Diff -0.0209 -0.0013 -0.0363 
CA S 0.1192 0.027 0.1667 0.046 0.0824 0.030
R 0.1429 0.027 0.1571 0.044 0.1327 0.034
Diff -0.0237 0.0096 -0.0503 
ICER 
PPA -- -- -- 
CA -- $29,640 -- 
Note: Dotted lines denote scenarios in which stepped care was dominated by repeat care 
(being more costly and less effective). Negative ICERs are not calculated. 
Abbreviations: CA: continuous abstinence, Diff: difference in estimates (cost, effect), 
ICER: incremental cost-effectiveness ratio, PPA: point-prevalence abstinence, R: repeat 
intervention, S: stepped care intervention, SE: standard error, UTHSC: University of 
Tennessee Health Science Center. 
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Table 4-4. Cost-Effectiveness of STEP Study, Women 
All Mayo UTHSC 
Variable Arm Mean SE Mean SE Mean SE 
Costs S $837.75 $52.72 $505.80 $68.80 $1,047.00 $55.47
R $438.73 $14.08 $356.92 $24.69 $495.26 $11.73
Diff $399.02 $148.88 $551.74 
PPA S 0.2 0.047 0.1724 0.071 0.2174 0.062
R 0.1935 0.041 0.2105 0.067 0.1818 0.053
Diff 0.0065 -0.0381 0.0356 
CA S 0.1067 0.036 0.1379 0.065 0.087 0.042
R 0.1075 0.032 0.1053 0.051 0.1091 0.042
Diff -0.0008 0.0326 -0.0221 
ICER 
PPA $61,388 -- $15,498 
CA -- $4,567 -- 
Note: Dotted lines denote scenarios in which stepped care was dominated by repeat care 
(being more costly and less effective). Negative ICERs are not calculated. 
Abbreviations: CA: continuous abstinence, Diff: difference in estimates (cost, effect), 
ICER: incremental cost-effectiveness ratio, PPA: point-prevalence abstinence, R: repeat 
intervention, S: stepped care intervention, SE: standard error, UTHSC: University of 
Tennessee Health Science Center. 
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Table 4-5. Cost-Effectiveness of STEP Study, Men 
All Mayo UTHSC 
Variable Arm Mean SE Mean SE Mean SE 
Costs S $911.94 $50.80 $704.32 $71.25 $1,108.90 $57.13
R $401.84 $15.66 $303.62 $21.20 $474.94 $14.43
Diff $510.10 $400.70 $633.96 
PPA S 0.2105 0.047 0.2703 0.074 0.1538 0.059
R 0.2667 0.051 0.25 0.078 0.2791 0.069
Diff -0.0562 0.0203 -0.1253 
CA S 0.1316 0.039 0.1892 0.065 0.0769 0.043
R 0.1867 0.045 0.2188 0.074 0.1628 0.057
Diff -0.0551 -0.0296 -0.0859 
ICER 
PPA -- $19,739 -- 
CA -- -- -- 
Note: Dotted lines denote scenarios in which stepped care was dominated by repeat care 
(being more costly and less effective). Negative ICERs are not calculated. 
Abbreviations: CA: continuous abstinence, Diff: difference in estimates (cost, effect), 
ICER: incremental cost-effectiveness ratio, PPA: point-prevalence abstinence, R: repeat 
intervention, S: rtepped care intervention, SE: standard error, UTHSC: University of 
Tennessee Health Science Center. 
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men) were $837.75 ($911.94), $505.80 ($704.32), and $1,047.00 ($1,108.90) overall, at 
Mayo, and at UTHSC, in that order. Conversely, costs for repeat intervention were higher 
for women, at $438.00 ($401.84), $356.92 ($303.62), and $495.26 ($474.94) among the 
same groups. Stepped care was cost-effective for women achieving continuous 
abstinence in the Mayo sample. Incremental cost-effectiveness in this population was 
$4,567 per quit. Stepped care yielded incremental cost-effectiveness ratios for point-
prevalence abstinence among all women, UTHSC women, and Mayo men; these 
estimates were $61,388, $15,498, and $19,739 per quit for the respective populations. 
Large cost and small effect differences yielded higher ICER estimates in these scenarios. 
Racial/ethnic differences in costs and effectiveness were evident; these data are 
presented in Table 4-6 and Table 4-7 for non-Hispanic white and ethnic minority 
populations, respectively. Intervention costs, in either arm, were lower for non-Hispanic 
whites versus ethnic minorities. Mean costs for stepped care and repeat interventions for 
whites were $800.61 and $400.86, respectively; these costs among ethnic minorities were 
$1,016.90 and $474.24, correspondingly. Similar differences in costs existed in the 
UTHSC sample. Comparisons across race were not feasible in the Mayo sample, due to 
underrepresentation of ethnic minorities. Non-Hispanic whites reported much higher rates 
of cessation compared to ethnic minorities. Point-prevalence estimates were nearly twice 
as high in both arms of the study overall among whites, at 24% versus 13% (stepped) and 
26% versus 14% (repeat). Continuous abstinence was also consistently higher among 
whites across study arms. Nearly 18% of whites using repeat intervention achieved 
abstinence compared to only 6% of ethnic minorities. In stepped intervention, continuous 
abstinence rates among whites and minorities were 15% and 6%, respectively. 
Differences in effectiveness were even larger within the UTHSC sample. Point-
prevalence abstinence was reported in 25% and 30% of white stepped and repeat 
intervention patients, compared to 13% and 14% of ethnic minorities. Only 4% and 5% 
of black stepped care and repeat intervention patients achieved continuous abstinence at 
study-end; whites achieved rates of 13% and 20% in corresponding study arms. Stepped 
care produced incremental cost-effectiveness ratios of $45,777 and $28,952 per quit in 
the Mayo sample for point-prevalence and continuous abstinence. 
Simulating Future Outcomes of Smoking Cessation 
Results of the long-term simulation are reported in Table 4-8. In general, 
encouraging smoking cessation through the STEP study was highly cost-effective.  Mean 
lifetime costs post-intervention were $49,025 per patient (95% CI: $6,320-$126,310) and 
yielded 8.62 QALYs (95% CI: 0.46-20.64 QALYs). Average cost-effectiveness was 
$6,530 per QALY (95% CI: $2,767-$19,441/QALY). Average age at model entry was 46 
years; average age at death was 59 years. Figure 4-1 displays the distribution of cost-
effectiveness estimates for the simulation. Blue bars indicate probability of cost-
effectiveness below $2,000, $4,000, etc. For example, one cost-effectiveness estimate fell 
below $2,000 per QALY; this is indicated in the 2000 bar. Fourteen estimates were 
$2,000-$3,000, at a probability of 0.044; these are displayed in the next bar. The red bars 
indicate where 10%, 50%, and 90% of cost-effectiveness estimates fell. Overall, 90% of 
cost-effectiveness estimates were less than $9,000 per QALY.  
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Table 4-6. Cost-Effectiveness of STEP Study, Non-Hispanic Whites 
All Mayo UTHSC 
Variable Arm Mean SE Mean SE Mean SE 
Costs S 800.61 45.134 636.1 54.665 1043.3 59.841
R 400.86 12.807 338.55 17.647 475.87 12.56
Diff 399.75 297.55 567.43 
PPA S 0.2424 0.0433 0.2373 0.0559 0.25 0.0693
R 0.2605 0.0404 0.2308 0.0527 0.2963 0.0627
Diff -0.0181 0.0065 -0.0463 
CA S 0.1515 0.0362 0.1695 0.0493 0.125 0.053
R 0.1765 0.0351 0.1538 0.0451 0.2037 0.0553
Diff -0.025 0.0157 -0.0787 
ICER 
PPA -- $45,777 -- 
CA -- $18,952 -- 
Note: Dotted lines denote scenarios in which stepped care was dominated by repeat care 
(being more costly and less effective). Negative ICERs are not calculated. 
Abbreviations: CA: continuous abstinence, Diff: difference in estimates (cost, effect), 
ICER: incremental cost-effectiveness ratio, PPA: point-prevalence abstinence, R: repeat 
intervention, S: stepped care intervention, SE: standard error, UTHSC: University of 
Tennessee Health Science Center. 
57 
Table 4-7. Cost-Effectiveness of STEP Study, Ethnic Minorities 
Ethnic Minorities 
All UTHSC 
Variable Arm Mean SE Mean SE 
Costs S $1,016.90 $58.19 $1,104.00 $53.29 
R $474.24 $16.27 $499.20 $13.20 
Diff $542.66 $604.80
PPA S 0.1346 0.048 0.1333 0.051 
R 0.1429 0.051 0.1364 0.052 
Diff -0.0083 -0.0031
CA S 0.0577 0.033 0.0444 0.031 
R 0.0612 0.035 0.0455 0.032 
Diff -0.0035 -0.0011
ICER 
PPA -- -- 
CA -- -- 
Note: Dotted lines denote scenarios in which stepped care was dominated by repeat care 
(being more costly and less effective). Negative ICERs are not calculated. 
Abbreviations: CA: continuous abstinence, Diff: difference in estimates (cost, effect), 
ICER: incremental cost-effectiveness ratio, PPA: point-prevalence abstinence, R: repeat 
intervention, S: stepped care intervention, SE: standard error, UTHSC: University of 
Tennessee Health Science Center. 
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Table 4-8. Cost-Effectiveness of Future Outcomes Simulation, Summary Statistics 
Statistic Cost Effect Cost/Eff Start age Death age 
Mean $49,025 8.62 Q $6,530 46.4 58.5
Std Dev $33,491 5.75 Q $3,535 11.1 10.6
Minimum $2,637 0.44 Q $1,401 22 27
2.50% $6,320 0.46 Q $2,767 26 37
10% $10,118 1.36 Q $3,639 31 45
Median $42,740 8.07 Q $5,976 47 58
90% $99,156 16.58 Q $8,686 61 73
97.50% $126,310 20.64 Q $19,441 68 78
Maximum $140,447 23.66 Q $29,236 82 83
Sum (n*mean) $15,638,951 2,750.62 Q -- -- --
Note: Estimates at 2.5% and 97.5% denote the lower and upper bounds of the 95% 
confidence interval. 
Abbreviations: Cost/Eff: cost-effectiveness (average), Q; QALY, Std Dev: standard 
deviation.   
 
Figure 4-1. Distribution of Cost-Effectiveness Ratios 
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Table 4-9 outlines outcomes of the original versus amended analyses. Differences 
across analyses reflect benefit of cessation following the STEP intervention. In the 
original simulation, 41 of 319 participants were abstinent at entry; of these, over half (24) 
remained abstinent until death. Nearly 22% of participants were quitters at death. Costs in 
the smoking simulation were $48,956 per person; this estimate was $69 lower than the 
original simulation. Fewer QALYs were gained in the smoking simulation when 
compared to the original (8.6 versus 8.62).  Participants in the original simulation did not 
live any longer than when in the smoking simulation. Age at death for each population 
was 58.5 years. The smoking simulation yielded two more cases of cerebrovascular 
disease, one more case each of emphysema and lung cancer, and two fewer cases of 
ischemic heart disease than the original group. In all, this was a net decrease of two cases 
of smoking-related disease. Incremental cost-effectiveness of successful STEP study 
cessation was $3,450 per QALY gained. 
Results of sensitivity analysis are reported in Table 4-10. These estimates account 
for changes in natural quit, disease incidence, mortality, cost and utility parameters. 
When considered individually, the largest drivers of incremental cost-effectiveness were 
cerebrovascular disease incidence (248% increase), lung cancer and emphysema 
incidence (155% increase for each) when set at their lower bounds and emphysema 
incidence at its upper bound (164% increase). Individual parameters yielding more 
favorable ICERs (compared to baseline) were ischemic heart disease mortality at its 
lower bound (17% decrease) and cerebrovascular disease incidence and natural quit rates 
when set at their upper bounds (12% and 7% decreases, respectively).When multiple 
factors were considered (costs, utilities, incidence, and mortality for all smoking-related 
diseases), changes in incremental cost-effectiveness ranged from cost-saving to 248% 
beyond baseline. When all parameters were set at lower bounds, simulation yielded 
smaller estimates. Participants in the original simulation yielded $32,842 in mean costs 
versus $32,578 in the smoking simulation. Original and smoking simulations yielded 8.17 
and 8.15 QALYs, respectively. Incremental cost-effectiveness was $13,200 per QALY 
gained. At the upper bound of sensitivity analysis, costs increased to $64,150 and 
$64,264 in original and smoking simulations. QALYs gained were higher, due to an 
increased percentage of quitting over the lifetime (8.79 and 8.77 QALYs). In this case the 
original simulation was cost-saving; successful quitters produced smaller mean costs. 
Average age at death remained unchanged in sensitivity analysis. Disease cases averted 
did change, however, ranging from an additional case of ischemic heart disease at lower 
bounds to two cases of disease averted at upper bounds (one case each of cerebrovascular 
disease and emphysema). Table 4-11 shows the impact of discounting on cost-
effectiveness estimates. Discount rates were adjusted in baseline analyses to five percent 
and zero percent (undiscounted). Costs ranged from $41,920-$65,479 in the original 
simulation and $41,863-$65,388 in the smoking simulations. Incremental cost-
effectiveness of successful quitting versus unsuccessful quitting ranged from $2,850-
$4,550 per QALY. 
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Table 4-9. Comparisons of Original and All Smokers Simulations 
Statistic Original All smokers 
Cost $49,025 $48,956
Effect 8.62 8.6
ACER $6,530 $6,643
Cost difference $69 --
Effect difference 0.02 --
ICER $3,450 --
Quits at entry 41 0
Quit %, smokers 21.6% 16.9%
SR disease, n 
IHD 32 30
CBD 11 13
LC 3 4
EMP 16 17
Age at death 58.5 58.5
Note: Baseline simulations discounted at 3%. All costs are presented in year 2009 U.S. 
dollars. Original simulation includes successful STEP study quitters. The ‘All smokers’ 
simulation assumes that all participants entered the model as smokers.  
Abbreviations: ACER: average cost-effectiveness ratio, CBD: cerebrovascular disease, 
EMP: emphysema, ICER: incremental cost-effectiveness ratio, IHD: ischemic heart 
disease, LC: lung cancer, n: number, SR: smoking-related. 
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Table 4-10. Sensitivity Analysis of Future Outcomes Simulations 
Param L/H Statistic O Sim AS Sim IC IE ICER Δ ICER % Δ 
Base -- Cost $49,025 $48,956 $69 0.02 $3,450 -- --
QALY 8.62 8.6
NQ 
Rate 
L Cost $48,934 $48,863 $71 0.02 $3,550 $100 3%
QALY 8.61 8.59
H Cost $49,166 $49,100 $66 0.02 $3,300 ($150) (4%)
QALY 8.64 8.62
QALY 8.79 8.78
IHD 
inc 
L Cost $48,682 $48,583 $99 0.02 $4,950 $1,500 43%
QALY 8.63 8.61
H Cost $49,179 $49,096 $83 0.02 $4,150 $700 20%
QALY 8.62 8.6
CBD 
inc 
L Cost $48,845 $48,725 $120 0.01 $12,000 $8,550 248%
QALY 8.62 8.61
H Cost $49,114 $49,053 $61 0.02 $3,050 ($400) (12%)
QALY 8.62 8.6
LC 
inc 
L Cost $48,976 $48,888 $88 0.01 $8,800 $5,350 155%
QALY 8.62 8.61
H Cost $49,075 $49,006 $69 0.02 $3,450 $0 0%
QALY 8.62 8.6
EMP 
inc 
L Cost $48,987 $48,899 $88 0.01 $8,800 $5,350 155%
QALY 8.62 8.61
H Cost $48,975 $48,884 $91 0.01 $9,100 $5,650 164%
QALY 8.62 8.61
IHD 
mort 
L Cost $48,855 $48,798 $57 0.02 $2,850 ($600) (17%)
QALY 8.62 8.6
H Cost $49,195 $49,115 $80 0.01 $8,000 $4,550 132%
QALY 8.62 8.61
CBD 
mort 
L Cost $48,963 $48,881 $82 0.02 $4,100 $650 19%
QALY 8.62 8.6
H Cost $49,087 $49,031 $56 0.01 $5,600 $2,150 62%
QALY 8.62 8.61
LC 
mort 
L Cost $48,976 $48,888 $88 0.02 $4,400 $950 28%
QALY 8.62 8.6
H Cost $49,073 $49,024 $49 0.01 $4,900 $1,450 42%
QALY 8.62 8.61
EMP 
mort 
L Cost $49,006 $48,936 $70 0.02 $3,500 $50 1%
QALY 8.62 8.6
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Table 4-10. (continued) 
Param L/H Statistic O Sim AS Sim IC IE ICER Δ ICER % Δ 
H Cost $49,044 $48,976 $68 0.01 $6,800 $3,350 97%
QALY 8.62 8.61
Costs L Cost $34,766 $34,492 $274 0.02 $13,700 $10,250 297%
QALY 8.62 8.6
H Cost $63,283 $63,420 ($137) 0.02 CS -- --
QALY 8.62 8.6
Util L Cost $49,025 $48,956 $69 0.02 $3,450 $0 0%
QALY 8.45 8.43
H Cost $49,025 $48,956 $69 0.01 $6,900 $3,450 100%
QALY 8.79 8.78
Inc 
(all) 
L Cost $48,537 $48,422 $115 0.02 $5,750 $2,300 67%
QALY 8.63 8.61
H Cost $49,349 $49,283 $66 0.02 $3,300 ($150) (4%)
QALY 8.62 8.6
Mort 
(all) 
L Cost $48,726 $48,635 $91 0.02 $4,550 $1,100 32%
QALY 8.62 8.6
H Cost $49,324 $49,278 $46 0.02 $2,300 ($1,150) (33%)
QALY 8.63 8.61
All L Cost $32,842 $32,578 $264 0.02 $13,200 $9,750 283%
QALY 8.17 8.15
H Cost $64,150 $64,264 ($114) 0.02 CS -- --
QALY 8.79 8.77
Note: Baseline simulations discounted at 3%. All costs are presented in year 2009 U.S. 
dollars. Original simulation (O Sim) includes successful STEP study quitters. The ‘All 
Smokers’ simulation (AS Sim) assumes that all participants entered the model as 
smokers. Low and high parameters denote values for 95% confidence intervals. 
Abbreviations: Δ: change in, %: percent, AS Sim: all smokers simulation, CBD: 
cerebrovascular disease, CS: cost-saving, EMP: emphysema, H: high, IC: incremental 
cost, IE: incremental effect, ICER: incremental cost-effectiveness ratio, IHD: ischemic 
heart disease, L: low, LC: lung cancer, L/H: low/high, O Sim: original simulation, Param: 
parameter, QALY: quality-adjusted life year, SR: smoking-related. 
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Table 4-11. Sensitivity Analysis, Discount Rate 
Baseline Discount: 5% Undiscounted 
Statistic Original Smokers Original Smokers Original Smokers
Cost $49,025 $48,956 $41,920 $41,863 $65,479 $65,388
Effect 8.62 8.60 7.48 7.46 11.19 11.17
ACE $6,530 $6,643 $6,473 $6,586 $6,624 $6,738
Cost Diff $69 -- $57 -- $91 --
Eff Diff 0.02 -- 0.02 -- 0.02 --
ICER $3,450 -- $2,850 -- $4,550 --
Note: Baseline simulations discounted at 3%. All costs are presented in year 2009 U.S. 
dollars. Original simulation includes successful STEP study quitters. The ‘All smokers’ 
simulation assumes that all participants entered the model as smokers.  
Abbreviations: ACE: average cost-effectiveness, Diff: difference, Eff: effect, ICER: 
incremental cost-effectiveness ratio. 
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Comparing STEP Cost-Effectiveness Analyses to the Literature 
The league tables previously reported in Chapter 2 were updated to include results 
of the current analyses. These results are reported in Table 4-12. STEP analysis is 
reported at the end of all studies reporting costs per quit. This reflects stepped care as a 
dominated strategy compared to repeat intervention. The long-term result is shown 
among studies reporting cost per QALY. This result falls near the middle of all estimates. 
Considering that STEP study participants received intervention as many as three times, 
the incremental cost-effectiveness estimate for long-term intervention was expected to be 
higher. However, at $3,450 per QALY, the Future Outcomes Simulation is highly cost-
effective.
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Table 4-12. Adjusted League Table, Cost-Effectiveness of Smoking Cessation 
Interventions 
Author Intervention Cost ($, 2009) 
Cost/Quit
Hall et al.  MM + PI vs. MM alone $545 
Feenstra et al.  MC vs. current practice $768 
Hall et al.  MM + Nortrip vs. MM alone $917 
Hall et al.  MM + Bupr vs. MM alone $1,868 
Woolacott et al. Counsel + Bupr vs. counsel $2,723 
Feenstra et al.  TC vs. current practice $2,798 
Feenstra et al.  MC + NRT vs. current practice $2,986 
Woolacott et al. Counsel + NRT + Bupr vs. counsel $3,795 
Feenstra et al.  IC + Bupr vs. current practice $4,112 
Woolacott et al. Counsel + NRT vs. counsel $4,264 
Feenstra et al.  IC + NRT vs. current practice $5,067 
Barnett et al.  Stepped care vs. Brief intervention $7,189 
STEP Study  Stepped care vs. repeat intervention Dominated 
Cost/Quality-Adjusted Life-Year 
Bolin et al.  Bupr vs. Patch (Males) cost-saving 
Bolin et al.  Bupr vs. Gum (Males) cost-saving 
Feenstra et al.  MC vs. current practice cost-saving 
Woolacott et al. Counsel + Bupr vs. counsel $1,008 
Woolacott et al. Counsel + NRT + Bupr vs. counsel $1,406 
Woolacott et al. Counsel + NRT vs. counsel $1,579 
Feenstra et al.  TC vs. current practice $1,877-$2,559 
Feenstra et al.  MC + NRT vs. current practice $2,389-$2,900 
Bolin et al.  Bupr vs. Patch (Females) $2,539 
STEP Study Successful quitters vs. non-quitters $3,450 
Bolin et al.  Bupr vs. Gum (Females) $4,054 
Feenstra et al.  IC + Bupr vs. current practice $5,801-$6,142 
Feenstra et al.  IC + NRT vs. current practice $8,360-$8,872 
Note: STEP Study intervention denoted in italics. 
Abbreviations: Bupr: bupropion; IC: intensive counseling; MC: minimal counseling; 
MM: medical management; Nortrip: nortriptyline; NRT: nicotine replacement therapy; 
PI: psychological intervention; TC: telephone counseling. 
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CHAPTER 5: CONCLUSIONS 
Discussion 
This study sought to evaluate the use of stepped care in smoking cessation 
interventions to increase cessation among smokers ready to quit. When compared to a 
repeated therapy intervention, stepped care did not prove cost-effective. Stepped care 
produced a greater percentage of continuous quitters only among women in the Mayo 
Clinic sample; this was the only scenario in which the ICER fell within estimates 
reported in the literature review in Chapter 2. Cessation rates favored stepped care in UT 
women, Mayo men, and the overall Mayo sample, but none of the differences observed 
were statistically significant. Thus, ICERs produced in these subgroups fell beyond the 
threshold of $10,000 per quit. However, when comparing alternatives that are considered 
equally efficacious, the general rule is to choose the strategy with the lower cost. In the 
case of STEP, repeat care dominated stepped care, as it was less costly and equally 
effective. As such, it would not be wise to recommend stepped care over repeated 
intervention. 
While stepped care was not proven cost effective, both study arms produced 
significant rates of continuous abstinence at two years. These rates, for both continuous 
and point-prevalence abstinence, are in line with results reported in short-term studies 
reviewed. Many of the short-term studies evaluated outcomes at one year or 18 months; 
STEP results are comparable at 24 months.  This study fills a large gap in the literature 
regarding rates of long-term abstinence after cessation intervention. The benefits seen 
with repeat care affirm newer findings by Fu and Han.105, 106 Fu and colleagues evaluated 
a sample of Veterans Affairs (VA) patients who had relapsed at six months post-tobacco 
cessation treatment, demonstrating that nearly two-thirds were interesting in recycling. 
The researchers also inquired about the type of treatment the smokers were interested in 
using; the majority were interested in combination pharmacotherapy and behavioral 
counsel.102 Han and colleagues examined a subset of patients who returned to a tobacco 
dependence clinic to receive repeat treatment(s) following initial relapse. Subsequent quit 
attempts by repeaters were similar to abstinence rates achieved in a larger sample 
receiving intervention once.106 
Several differences were noted among participants across study sites, race, and 
gender. First, participation rates were quite different across sites, with nearly three-fold 
greater attendance at all visits among UTHSC versus Mayo participants. Unfortunately, 
increased participation did not impact quitting. CES-D scores were higher among 
UTHSC versus Mayo Clinic, and specifically in the stepped care arm. This could have 
likely influenced lower levels of quitting at the UTHSC site. Differences in efficacy 
observed across race and gender also require further discussion. Non-Hispanic whites 
achieved higher rates of cessation versus ethnic minorities, as did men (versus women). 
A variety of factors may have contributed to these differences, but that discussion extends 
beyond the scope of this analysis. The low rates achieved by ethnic minorities are 
concerning, suggesting that neither repeated nor stepped care was beneficial for achieving 
cessation. In fact, the continuous abstinence rate observed in ethnic minorities was 
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similar to one reported by Hughes which was based on self-quitting. That such a 
significant portion of minorities participated in the study is moderately encouraging; 
however, the results are still disappointing. Data affirm that success rates among ethnic 
minorities are generally lower, despite making as many or more quit attempts compared 
to white smokers.107-109 Qualitative studies, specifically those addressing barriers to 
treatment delivery, use, or success, might play a significant role in informing future 
research in this population.33, 109 
The results of the future outcomes simulation were very positive. Study 
intervention produced a cost-effectiveness estimate that was extremely cost-effective 
when compared to other studies in the literature. Average age at death in the original 
simulation was no higher than in the smoking simulation; smoking cessation did not 
impact age at death, but did impact cause. Ultimately, participants in whom smoking-
related disease was averted died from other causes. In sensitivity analysis, cost-
effectiveness remained favorable, but benefits of cessation related to disease incidence 
were lost, especially when disease incidence decreased or more smokers quit on their 
own. Successful smoking cessation impacted incidence of emphysema, lung cancer, and 
cerebrovascular disease, but not ischemic heart disease. This is likely due to the fact that 
smoking is only attributable to one-fifth of ischemic heart disease incidence.10 Overall, 
the impact of decreased smoking-related disease incidence yielded an attractive estimate 
of incremental cost-effectiveness. Results of the future outcomes simulations demonstrate 
the importance and economic feasibility of investing in smoking cessation, even in small 
populations.  
Strengths 
This study has a number of strengths. First, the underlying study is comprised of a 
diverse mix of smokers, especially those of ethnic minority or low income populations. 
As mentioned previously, these are two smoking groups that have been challenged with 
disparate access to therapy and ultimately difficulties with successful cessation. The 
literature evaluating smoking cessation interventions among these two key groups is still 
sparse. This study confirms that continued research is warranted to address tobacco 
dependence among ethnic minorities. Also, using the assumption of smoking for patients 
missing the final visit likely provides a conservative estimate of efficacy and cost-
effectiveness. This strategy is generally employed in smoking cessation studies for 
persons lost to follow-up.  
In terms of the simulation of future outcomes, the data sources utilized were 
relatively new, using the most recent year(s) available. Moreover, these data are 
nationally representative, providing reliable estimates of disease incidence, mortality risk, 
healthcare costs and utilities across age, race, and gender. In addition, the model 
constructed for simulation of future health outcomes was derived from various models 
which have been widely used in the literature.94, 95 It accounts for a wider variety of 
tobacco-related diseases than earlier single-disease models. However, it is not as complex 
as a newer cessation model, which encompasses 14 tobacco-related diseases.85 Given the 
uncertainty about the disease pathways that smokers follow after cessation, only more 
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common smoking-related diseases were captured. Because of this, long-term cost-
effectiveness analysis likely underestimates the economic benefits of quitting. Further, 
the model did not account for productivity gains associated with smoking cessation or 
gains associated with reallocation of resources used to purchase tobacco products. Other 
economic impacts of smoking cessation on society are also ignored. For example, 
smoking cessation reduces involuntary exposure to tobacco smoke, potentially averting 
cases of illness caused by secondhand smoke.  
Limitations 
Results of the cost-effectiveness analysis of stepped care versus repeat care must 
be interpreted with caution. It must be noted that UTHSC patients in the analysis sample 
reported higher CES-D scores and baseline carbon monoxide readings than the remaining 
group. The extent to which these variables might influence other outcomes is unknown. 
Moreover, the study was not powered to detect significant differences in cost-
effectiveness. Especially among joint clinical/economic studies, underlying studies may 
be adequately powered for clinical outcomes, but inadequately powered for economic 
outcomes.110 To achieve joint power, much larger sample sizes are required; this 
introduces potential ethical and practical issues.111 Several methods have been put 
forward to power studies for economic outcomes, but these techniques have not yet been 
widely employed in cost-effectiveness analyses.112-117 The current study utilized 
confidence interval estimation to characterize uncertainty around cost-effectiveness 
estimates; this technique is a generally accepted alternative to hypothesis testing or power 
calculations.118-121 
Next, the extent to which the demographic profile of STEP participants resembles 
the current smoking population in the United States will impact the generalizability of 
results to a larger group. A key limitation here is related to the absence of certain special 
populations of smokers in the study, including those who were pregnant, had psychiatric 
comorbidities or other medical conditions deemed ineligible for inclusion. Smoking 
cessation interventions containing pharmacotherapy have not yet been deemed 
appropriate for pregnant smokers; as such, no statement regarding cost-effectiveness of 
this particular stepped care intervention can be made for them. In addition, results cannot 
be extended to other key smoking populations not represented in the STEP study. 
Another limiting factor in this analysis is related to the study setting. Study participants, 
though diverse, may not be representative of the larger smoking population, as their 
interest in participating in STEP may differentiate them from other smokers. Receipt of 
free medication and compensation for time may have impacted participation throughout 
the study. As such, the outcomes observed in STEP may not be reflected in natural 
settings. Finally, the reliability of the results obtained in the simulation wholly depends 
on the accuracy of assumptions made in structure of and data used in the model. 
In the long-term model evaluating future outcomes of smoking cessation, utilities 
were derived using a mapping algorithm from Sullivan. Other algorithms have been used 
similarly to map between SF-12 and EQ-5D scores, including one by Brazier.122 Use of 
mapping techniques may not accurately reflect utilities among this or a community-based 
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population. Another issue to consider in use of HRQL scores is the ensuing debate 
regarding racial/ethnic differences in valuation and its impact on cost-effectiveness 
research. Wang, Saalfrank, and Gaskin have demonstrated through literature review and 
other analysis that racial and ethnic differences do exist.123-125 Further, they emphasize a 
need for research to explore factors influencing these differences and to use caution when 
applying health-related quality of life across diverse populations in cost-utility analysis. 
For this reason, utilities used in the model were not adjusted for race/ethnicity to avoid 
biases in the cost-effectiveness measures. 
Promoting Smoking Cessation in Primary Care 
Greater efforts are needed for integrating smoking cessation treatment into 
primary care practice. The primary care setting is considered the most appropriate for 
addressing tobacco dependence; opportunities exist for repeated intervention by 
physicians, nurses, pharmacists, and dentists, among others. However, provision of 
support for smoking cessation has not been a priority for general clinicians, as evidenced 
in a recent report. An analysis conducted by Maciosek and colleagues revealed 
significant underutilization of preventive services for smoking cessation.126 Using 2005 
HEDIS data, the researchers found that 48% of smokers received advice to quit from 
physicians, while only 28% of smokers reported receiving medical assistance to quit. 
They surmised that if the percentage offered assistance were increased to 90%, an 
additional 42,000 lives might be saved. Similar inconsistencies in intervention among 
providers have been documented in the Guidelines and other literature.  
The design of the STEP study provides a feasible model for smoking cessation 
intervention in the primary care setting.  Research indicates that smokers make more 
visits per year to a physician than non-smokers.11 These primary care visits could serve as 
treatment visits, in which physicians or nurses could assess smoking status, gauge 
readiness and commitment to quit, provide counseling and/or pharmacotherapy, and 
schedule follow-up. Telephone follow-up could be conducted by a nurse or staff person 
to provide support until the next visit. At subsequent visits, quit status could be assessed 
and repeated intervention employed if necessary until a quit is achieved.  Provision of 
continuous intervention is key; it has been shown to increase cessation nearly four-fold 
when compared to one-time intervention.127 Follow-up through and beyond 12 months 
post-cessation is equally critical for ensuring long-term success.  
Economic Evaluation for Healthcare Financing  
In many countries, the formal use of economic evaluation is mandated to guide 
healthcare financing (including coverage of healthcare medications and treatments). 
Since 1992, Australia, Canada, Portugal, Finland, and the Netherlands have formalized 
and issued guidelines on the systematic use of economic evaluation in healthcare policy 
and decision making. More recently, the United Kingdom established an independent 
organization, National Institute for Health and Clinical Excellence (NICE), to provide 
clinical and economic guidance in public health, health technologies, and clinical 
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practice. In other European countries, informal guidelines have been established to 
achieve these aims. In the United States, informal guidelines or recommendations have 
been published, but their use is not enforced. As such, Gold and colleagues emphasize a 
need for standardization, due to the increased use of economic data in guiding allocation 
of healthcare resources. 
While growth of economic evaluation in healthcare decision-making is 
acknowledged, it has yet to be wholly embraced as a systematic tool for justifying 
healthcare financing. Given the extent to which cost-effectiveness drives approval of new 
medicines in the United Kingdom, researchers there assert that even where the best 
possible economic evaluations are available, they are only one element in a complex 
process of decision-making that is also shaped by what is politically feasible. In the 
United States, Williams and colleagues highlight two key barriers to the use of economic 
analyses in healthcare—accessibility and acceptability of research evidence.128 
Difficulties in interpretation of data (due to lack of statistical expertise) and presentation 
of results hamper the accessibility of economic evaluation for decision-making. In 
addition, acceptance of economic evaluation hinges on decision-makers’ perception of its 
relevance in addressing emerging health needs. A focus group study evaluating 
usefulness of economic evaluations found that decision makers valued information on 
cost-effectiveness, but suggested methodological improvements to increase the reliability 
of economic studies.129 A small body of literature has surfaced in the last decade, which 
promotes incorporating the scientific rigors of clinical studies into economic evaluations. 
Several researchers have proposed the adoption of hypothesis testing and put forth 
various methods for constructing confidence intervals and performing sample size and 
power calculations.113, 115-117 In Europe, the generalized cost-effectiveness analysis has 
been developed to address shortcomings of previous economic evaluations. 
Gold and colleagues assert that improvements in the standardization of cost-
effectiveness analysis methods will allow progress toward more systematic use of CEA in 
policy- and decision-making, especially for the United States. In the meantime, the health 
system will continue to use other implicit or explicit means to allocate limited resources. 
Whether through formal means of cost-effectiveness analysis or otherwise, healthcare 
payers in the U.S. are using clinical and economic evidence in their considerations of 
coverage of tobacco cessation pharmacotherapies and related programs. Phillips-Tangum 
and colleagues have studied trends in health plan coverage of smoking cessation 
therapies; their recent analysis found that coverage for any tobacco dependence treatment 
increased from 25 percent of health plans in 1997 to 88 percent of health plans in 2003, 
the most recent year data were available.130 The authors attributed this increase in 
coverage to the growing body of literature indicating that reducing treatment costs is 
associated with greater use of tobacco cessation programs and services, which can 
increase rates of cessation.  
Medicaid is one payer that has given particular attention to the economic benefits 
of smoking cessation treatment coverage. Whereas smokers comprise one-fifth of the 
general population, one-third of Medicaid enrollees are current smokers. Medicaid 
coverage of smoking cessation therapies and counseling increased substantially from 
2002-2006.131 At the end of 2002, 36 Medicaid programs covered some tobacco-
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dependence counseling or medication for all Medicaid recipients, four states offered 
coverage only for pregnant women, two states offered coverage for all pharmacotherapy 
and counseling treatments recommended by the 2000 PHS guideline, and seven states 
covered all recommended medications and at least one form of counseling. By 2006, 39 
state Medicaid programs (including the District of Columbia) covered some form of 
tobacco-dependence treatment (i.e., medication or counseling) for all Medicaid recipients 
and one state program provided coverage for all recommended treatments. Two states 
that previously provided no coverage for tobacco-dependence treatment began coverage 
in 2006. In addition, 32 states added coverage for varenicline (Chantix™ [Pfizer, 
Mission, Kansas]), one state expanded its coverage to include the nicotine lozenge, and 
one state expanded coverage to include individual counseling.131 
Despite inherent limitations of economic evaluation as a complete tool for 
healthcare decision-making, the overwhelming affirmation of the cost-effectiveness of 
smoking cessation therapies indicates that any future economic evaluations will continue 
to influence (formally or informally) greater coverage of pharmacotherapies and adoption 
of novel interventions and programs to promote cessation efforts. A new report by the 
Pacific Center on Health and Tobacco has proposed integrating telephone quitlines into 
healthcare systems.132 The need for referrals among quitlines and referral sources among 
healthcare systems creates a unique opportunity for partnership. The report documented 
initiatives taken by several states to develop enhanced smoking cessation service 
networks. Smoking cessation is also a key focus in the healthcare platform of the current 
presidential administration; economic stimulus bills presented to Congress have included 
over $75 million for funding smoking cessation campaigns and purchasing equipment for 
smoking research. 
Future Directions 
 Newer tobacco control initiatives targeting current smokers are increasingly 
focused on technology-based methods for increasing cessation. Given the popularity of 
the iPhone™ [Apple, Inc.], the National Tobacco Cessation Collaborative (NTCC) and  
George Washington University School of Public Health and Health Services have 
developed an application, “My Quitline”, to help smokers quit. The free application, once 
downloaded, will place users in direct contact with National Cancer Institute’s quitline 
counselors via phone or text. Mobile-phone based programs in the U.S. have targeted 
young adults, particularly college students, with some success.133, 134 Bock and her 
colleagues, in 2008, updated a previous review of the quality of web-assisted tobacco 
interventions (WATIs).135 Their search yielded over 80 websites claiming to offer U.S. 
smokers assistance with quitting smoking, but only one-fourth of these met Guidelines 
criteria. The excluded websites sold smoking-cessation programs rather than providing 
support for smokers wanting to quit. Their findings, however, did suggest improvement 
in quality of websites in providing advice to quit, offering practical counseling, and 
enhancing motivation to quit. The researchers proposed further research on maximizing 
interactive capabilities (personalizing treatment, providing a virtual support system, 
facilitating follow-up) of smoking cessation websites to improve outcomes.135 While 
technology-based methods are promising, their success depends on their ability to affect 
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the remaining smoking population. Telephone quitlines have improved in this regard, 
with a new study showing increased reach among ethnic minorities as well as older, less 
educated, heavier smokers.57 
Conclusions 
Stepped care cannot be dismissed yet as a viable method for improving smoking 
cessation rates. In the most recent update of the Guidelines, both the inconsistency of 
results and overall paucity of literature kept panel members from recommending stepped 
care or tailored methods for smoking cessation. Since the update, two other studies have 
evaluated the use of stepped therapy in a smoking cessation intervention and reported 
positive results. Christenhusz et al evaluated use of stepped care intervention in smokers 
with moderate to severe COPD.136 Usual care participants received a brief counseling 
intervention with an opportunity to receive pharmacotherapy at cost; stepped care 
participants received individual and group counseling and bupropion. If stepped care 
patients lapsed within three months, additional counseling was provided. Usual care 
participants received no further intervention. Ultimately, higher rates of continuous 
abstinence at one year for stepped care versus usual care (19% versus 9%) were reported. 
Further, logistic regression results found no baseline characteristics (i.e. attitude toward 
quitting, baseline cotinine value) to significantly predict cessation in the stepped care 
arm, indicating that less-motivated smokers could benefit from intensive stepped care 
therapy. Barnett et al applied a stepped care intervention to smokers in a mental health 
setting.77 Usual care participants received brief counsel and a list of available smoking 
cessation services. Stepped care patients received up to three assessments of readiness to 
quit, with contemplators or requestors receiving 10 weeks of NRT therapy and 
counseling. Upon relapse, additional counseling was provided. At 18-month follow-up, 
24.6% of stepped care patients versus 19.1% of usual care patients achieved point-
prevalent cessation. Incremental cost-effectiveness of stepped care was $6,204 per quit. A 
large-scale study of stepped care (n= 3,024) has been conducted in Spain; the results have 
not yet been reported.137 
 Future studies of stepped care in smoking cessation will need to provide solid 
evidence of its effectiveness before any formal recommendation can be made. Particular 
emphasis should be placed on development of standardized study protocols. Published 
studies evaluating stepped care have lacked agreement on decision criteria for 
implementing subsequent steps for stepped care interventions. Four studies used relapse 
as the determinant for intensifying therapy,74, 77, 136, 138 while the remainder used looser 
criteria for initiating subsequent steps.75, 139 Additionally, one study attributed poor results 
to inconsistency of staff follow-up.136 Research investigating optimal timing and content 
of interventions is also warranted; Smith and Reid mentioned these as contributors to 
poor study outcomes.74, 75 If stepped care in smoking cessation is to become viable, 
researchers will need to explore and implement factors that have influenced its success in 
treatment of other various chronic diseases, especially substance abuse disorders. 
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